CDC tried to hide the results of its VAERS signal detection data from ICAN and the rest of the country. When you understand this data, you will also understand why. According to CDC's VAERS Standard Operating Procedures, a “safety signal” is defined as a condition that has a PRR>=2.00, N>=3, and Chi-Square>=4.00. And as you will see below, numerous concerning conditions blow these numbers away! To download all PRR data (excel files), click here.

Currently selected: CDC Proportional Reporting Ratio

5 Yrs.–11 Yrs. 12 Yrs.–17 Yrs. 18+ SERIOUS 5 Yrs.–11 Yrs. SERIOUS 12 Yrs.–17 Yrs. SERIOUS 18+

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• AGES 5 YEARS-11 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• AGES 5 YEARS-11 YEARS excludes missing ages

MedDRA Codes ALL Reports (5 Yrs-11 Yrs)	12/14/2020-03/18/2022 COVID19 mRNA N=9256	01/01/2009-03/18/2022 NON-COVID19 N=49819	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
PRODUCT PREPARATION ISSUE	1506	37	8043.27	219.08	158.23	303.33
COVID-19	133	4	682.64	178.96	66.21	483.74
INCORRECT DOSE ADMINISTERED	1501	251	6691.23	32.19	28.21	36.72
UNDERDOSE	397	81	1650.96	26.38	20.79	33.47
PRODUCT ADMINISTRATION ERROR	61	8	271.12	41.04	19.65	85.73
IMMUNISATION	71	13	296.64	29.40	16.28	53.08
ILLNESS	25	3	109.39	44.85	13.55	148.52
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1217	439	4306.57	14.92	13.41	16.60
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	209	86	678.99	13.08	10.19	16.80
INCORRECT PRODUCT FORMULATION ADMINISTERED	141	60	448.93	12.65	9.36	17.10
APPENDICITIS	16	4	57.89	21.53	7.20	64.38
PRODUCT PREPARATION ERROR	122	75	316.63	8.76	6.57	11.66
MYOCARDITIS	14	4	47.97	18.84	6.20	57.22
INJURY ASSOCIATED WITH DEVICE	12	3	42.25	21.53	6.08	76.28
PRODUCT USE ISSUE	23	10	68.91	12.38	5.89	26.00
ANGINA PECTORIS	11	3	37.31	19.74	5.51	70.73
PHARYNGEAL SWELLING	12	4	38.27	16.15	5.21	50.05
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	50	34	119.14	7.92	5.12	12.23
MENSTRUATION IRREGULAR	10	3	32.43	17.94	4.94	65.18
OROPHARYNGEAL DISCOMFORT	10	3	32.43	17.94	4.94	65.18
NEEDLE ISSUE	13	6	36.13	11.66	4.43	30.67
CHEST PAIN	164	188	253.91	4.70	3.81	5.78
SYRINGE ISSUE	37	34	68.72	5.86	3.68	9.33
PERIORBITAL SWELLING	13	8	30.58	8.75	3.63	21.10
NO ADVERSE EVENT	1996	2839	2612.62	3.78	3.59	3.99
CONJUNCTIVITIS	28	25	52.66	6.03	3.52	10.33
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	38	38	65.31	5.38	3.44	8.43
VACCINATION FAILURE	16	12	33.40	7.18	3.40	15.16
OVERDOSE	20	17	38.43	6.33	3.32	12.08
APPENDICECTOMY	12	8	26.50	8.07	3.30	19.75
KAWASAKI'S DISEASE	7	3	18.42	12.56	3.25	48.56
PITYRIASIS ROSEA	8	4	19.92	10.76	3.24	35.74
CHEST DISCOMFORT	60	81	75.29	3.99	2.86	5.56
PAINFUL RESPIRATION	12	10	22.32	6.46	2.79	14.94
PRODUCT STORAGE ERROR	461	807	418.14	3.07	2.75	3.44
OFF LABEL USE	21	25	29.09	4.52	2.53	8.07
EXPIRED PRODUCT ADMINISTERED	271	510	215.48	2.86	2.47	3.31
SLEEP DISORDER	31	44	35.52	3.79	2.40	6.00
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	39	63	37.69	3.33	2.24	4.96
FATIGUE	391	860	233.79	2.45	2.18	2.75
VENTRICULAR EXTRASYSTOLES	5	3	9.97	8.97	2.14	37.53
FEELING COLD	33	57	28.51	3.12	2.03	4.78
ADVERSE EVENT	12	15	14.82	4.31	2.02	9.20
SWELLING OF EYELID	13	17	15.35	4.12	2.00	8.47
PALPITATIONS	31	54	26.32	3.09	1.99	4.80
INCORRECT ROUTE OF PRODUCT ADMINISTRATION	18	27	18.38	3.59	1.98	6.51
SHOCK	7	7	10.03	5.38	1.89	15.34
CHILLS	145	344	71.91	2.27	1.87	2.75
SEIZURE	100	232	51.68	2.32	1.84	2.93
FEEDING DISORDER	9	11	10.90	4.40	1.83	10.62
HEAD DISCOMFORT	10	13	11.44	4.14	1.82	9.44
AXILLARY PAIN	27	51	19.81	2.85	1.79	4.54
MOUTH SWELLING	7	8	8.69	4.71	1.71	12.98
LYMPHADENOPATHY	70	169	32.67	2.23	1.69	2.94
CONDITION AGGRAVATED	89	226	37.01	2.12	1.66	2.71
AGEUSIA	4	3	6.24	7.18	1.61	32.06
CARDIAC DISORDER	4	3	6.24	7.18	1.61	32.06
SYNOVITIS	12	20	9.96	3.23	1.58	6.60
ABDOMINAL PAIN LOWER	7	9	7.54	4.19	1.56	11.24
MUSCULOSKELETAL CHEST PAIN	7	9	7.54	4.19	1.56	11.24
INJECTION SITE EXTRAVASATION	6	7	6.98	4.61	1.55	13.72
HAEMATURIA	10	17	7.79	3.17	1.45	6.91
GENERALISED TONIC-CLONIC SEIZURE	21	48	10.31	2.35	1.41	3.93
TINNITUS	20	45	10.12	2.39	1.41	4.05
GRIMACING	6	8	5.91	4.04	1.40	11.63
WOUND	6	8	5.91	4.04	1.40	11.63
INJECTION SITE PARAESTHESIA	5	6	5.30	4.49	1.37	14.69
NEPHROTIC SYNDROME	5	6	5.30	4.49	1.37	14.69
LIMB DISCOMFORT	18	41	8.75	2.36	1.36	4.11
GIANOTTI-CROSTI SYNDROME	4	4	4.78	5.38	1.35	21.52
NERVOUSNESS	22	54	9.17	2.19	1.34	3.60
VOMITING PROJECTILE	7	11	5.69	3.43	1.33	8.83
ADVERSE REACTION	10	19	6.41	2.83	1.32	6.09
HYPOPNOEA	7	12	4.95	3.14	1.24	7.97
LIP BLISTER	5	7	4.33	3.84	1.22	12.11
HEART RATE DECREASED	15	37	5.88	2.18	1.20	3.97
HAEMORRHAGE	12	28	5.18	2.31	1.17	4.53
DERMATITIS	6	10	4.24	3.23	1.17	8.88
PANIC ATTACK	9	19	4.57	2.55	1.15	5.63
DRY EYE	4	3	6.24	7.18	1.61	32.06
MOTION SICKNESS	4	3	6.24	7.18	1.61	32.06
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE	13	22	10.65	3.18	1.60	6.31
ABDOMINAL DISCOMFORT	44	112	17.67	2.11	1.49	2.99
ALOPECIA AREATA	6	8	5.91	4.04	1.40	11.63
CHAPPED LIPS	6	8	5.91	4.04	1.40	11.63
ORAL MUCOSAL ERUPTION	5	6	5.30	4.49	1.37	14.69
SENSATION OF FOREIGN BODY	9	18	5.11	2.69	1.21	5.99
INTERCHANGE OF VACCINE PRODUCTS	9	19	4.57	2.55	1.15	5.63
DRY SKIN	13	33	4.61	2.12	1.12	4.03
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	33	1	164.45	177.62	24.30	1298.48
BELL'S PALSY	15	1	68.05	80.74	10.67	611.12
DRUG INEFFECTIVE	14	2	57.18	37.68	8.56	165.75
LEFT VENTRICULAR DYSFUNCTION	9	1	36.39	48.44	6.14	382.30
MENSTRUAL DISORDER	8	2	26.65	21.53	4.57	101.37
COSTOCHONDRITIS	7	2	21.79	18.84	3.91	90.67
TASTE DISORDER	7	2	21.79	18.84	3.91	90.67
PERICARDIAL EFFUSION	6	1	20.96	32.29	3.89	268.21
PERICARDITIS	6	1	20.96	32.29	3.89	268.21
POOR QUALITY PRODUCT ADMINISTERED	6	1	20.96	32.29	3.89	268.21
APHONIA	5	2	12.52	13.46	2.61	69.34
APHTHOUS ULCER	5	2	12.52	13.46	2.61	69.34
SINUS TACHYCARDIA	5	2	12.52	13.46	2.61	69.34
DEVICE CONNECTION ISSUE	4	2	8.27	10.76	1.97	58.76
HEPATOMEGALY	4	2	8.27	10.76	1.97	58.76
OCULAR DISCOMFORT	4	2	8.27	10.76	1.97	58.76
PAROSMIA	4	2	8.27	10.76	1.97	58.76
BLOOD PRESSURE DIASTOLIC DECREASED	3	1	6.64	16.15	1.68	155.21
STRAWBERRY TONGUE	3	1	6.64	16.15	1.68	155.21
TRICUSPID VALVE INCOMPETENCE	3	1	6.64	16.15	1.68	155.21
HORDEOLUM	3	2	4.46	8.07	1.35	48.31
PLEURAL EFFUSION	3	2	4.46	8.07	1.35	48.31
PRODUCT ADMINISTRATION INTERRUPTED	3	2	4.46	8.07	1.35	48.31
RESPIRATORY SYNCYTIAL VIRUS INFECTION	3	2	4.46	8.07	1.35	48.31
TENSION HEADACHE	3	2	4.46	8.07	1.35	48.31
VACCINATION SITE URTICARIA	3	2	4.46	8.07	1.35	48.31
BEHAVIOUR DISORDER	4	1	11.17	21.53	2.41	192.60

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• AGES 12 YEARS-17 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• AGES 12 YEARS-17 YEARS excludes missing ages

MedDRA Codes ALL Reports (12 Yrs-17 Yrs)	12/14/2020-03/18/2022 COVID19 mRNA N=21791	01/01/2009-03/18/2022 NON-COVID19 N=48026	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
COVID-19	458	3	1000.32	336.47	108.13	1046.99
MYOCARDITIS	709	12	1525.71	130.22	73.62	230.33
UNDERDOSE	959	58	1910.04	36.44	27.97	47.48
HEAVY MENSTRUAL BLEEDING	123	5	248.42	54.22	22.18	132.56
PERICARDITIS	210	12	413.77	38.57	21.56	68.99
PRODUCT PREPARATION ISSUE	516	57	928.90	19.95	15.18	26.22
ILLNESS	72	5	136.44	31.74	12.82	78.55
ANTICOAGULANT THERAPY	53	4	98.52	29.20	10.57	80.67
PERICARDIAL EFFUSION	67	7	118.70	21.09	9.69	45.94
PRODUCT ADMINISTRATION ERROR	47	4	85.48	25.90	9.33	71.87
AGEUSIA	66	8	113.29	18.18	8.73	37.87
IMMUNISATION	96	14	158.67	15.11	8.63	26.47
ANGINA PECTORIS	48	5	84.29	21.16	8.42	53.14
PLEURITIC PAIN	48	5	84.29	21.16	8.42	53.14
CHEST PAIN	1760	463	2457.68	8.38	7.57	9.27
PAINFUL RESPIRATION	131	26	197.49	11.10	7.29	16.91
PHARYNGEAL SWELLING	74	14	112.30	11.65	6.58	20.62
FEAR OF INJECTION	35	5	56.47	15.43	6.05	39.37
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1425	532	1621.22	5.90	5.35	6.51
RESPIRATORY RATE INCREASED	174	53	216.91	7.24	5.32	9.84
VENTRICULAR EXTRASYSTOLES	33	6	49.38	12.12	5.08	28.92
PULMONARY EMBOLISM	29	5	43.86	12.78	4.95	33.02
TRICUSPID VALVE INCOMPETENCE	25	4	38.35	13.77	4.79	39.57
PRODUCT STORAGE ERROR	1977	853	2050.04	5.11	4.72	5.53
RESPIRATORY RATE DECREASED	42	10	57.24	9.26	4.65	18.44
CHEST DISCOMFORT	609	251	634.19	5.35	4.62	6.19
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	463	192	478.05	5.31	4.50	6.28
BLOOD PRESSURE INCREASED	170	63	187.85	5.95	4.46	7.94
SINUS ARRHYTHMIA	29	6	41.13	10.65	4.42	25.65
APPENDICITIS	58	17	72.25	7.52	4.38	12.91
THROMBOSIS	32	8	42.13	8.82	4.06	19.13
PERIORBITAL SWELLING	21	4	30.05	11.57	3.97	33.70
ACUTE KIDNEY INJURY	31	8	40.14	8.54	3.93	18.58
OROPHARYNGEAL DISCOMFORT	38	11	46.91	7.61	3.89	14.89
INTENSIVE CARE	341	161	315.77	4.67	3.87	5.63
HEART RATE INCREASED	434	212	391.27	4.51	3.83	5.31
VAGINAL ULCERATION	25	6	33.03	9.18	3.77	22.38
INCORRECT DOSE ADMINISTERED	678	351	583.33	4.26	3.75	4.84
SINUS TACHYCARDIA	61	22	67.24	6.11	3.75	9.95
FLUSHING	389	194	343.66	4.42	3.72	5.25
MENSTRUAL DISORDER	74	30	75.54	5.44	3.56	8.31
APHTHOUS ULCER	19	4	25.96	10.47	3.56	30.77
CARDIAC DISORDER	25	7	30.67	7.87	3.41	18.20
CARDIAC FLUTTER	25	7	30.67	7.87	3.41	18.20
PRODUCT TEMPERATURE EXCURSION ISSUE	27	8	32.30	7.44	3.38	16.37
IMMUNE THROMBOCYTOPENIA	20	5	25.50	8.82	3.31	23.49
TACHYPNOEA	66	29	63.09	5.02	3.24	7.76
PALPITATIONS	347	200	265.15	3.82	3.22	4.55
ELECTROCARDIOGRAM T WAVE INVERSION	15	3	20.42	11.02	3.19	38.06
HEART SOUNDS ABNORMAL	15	3	20.42	11.02	3.19	38.06
OVERDOSE	37	15	36.83	5.44	2.98	9.90
LYMPHOPENIA	14	3	18.40	10.29	2.96	35.79
LYMPHADENOPATHY	444	296	287.36	3.31	2.86	3.83
AXILLARY PAIN	94	52	73.44	3.98	2.84	5.59
DYSMENORRHOEA	63	32	52.98	4.34	2.84	6.64
SLEEP DISORDER	150	93	104.35	3.55	2.75	4.60
PAROSMIA	24	9	24.60	5.88	2.73	12.64
TACHYCARDIA	321	224	194.83	3.16	2.66	3.74
NEEDLE ISSUE	18	6	19.45	6.61	2.62	16.65
RESPIRATORY SYMPTOM	18	6	19.45	6.61	2.62	16.65
HYPERHIDROSIS	1102	859	585.42	2.83	2.59	3.09
MOUTH SWELLING	21	8	21.06	5.79	2.56	13.06
DYSPNOEA EXERTIONAL	45	24	35.63	4.13	2.52	6.78
APPENDICECTOMY	46	25	35.77	4.06	2.49	6.60
SENSITIVE SKIN	12	3	14.44	8.82	2.49	31.24
SINUS BRADYCARDIA	28	13	24.57	4.75	2.46	9.16
TRANSAMINASES INCREASED	17	6	17.60	6.24	2.46	15.84
DYSPNOEA	1244	1030	603.16	2.66	2.45	2.89
PRODUCT PREPARATION ERROR	152	107	90.13	3.13	2.45	4.01
UNRESPONSIVE TO STIMULI	633	511	314.03	2.73	2.43	3.06
EXPIRED PRODUCT ADMINISTERED	559	453	274.95	2.72	2.41	3.08
DECREASED ACTIVITY	50	29	36.43	3.80	2.41	6.00
HYPOTENSION	343	269	176.19	2.81	2.40	3.29
SWELLING OF EYELID	33	17	26.61	4.28	2.38	7.68
STEROID THERAPY	18	7	17.53	5.67	2.37	13.57
ACUTE RESPIRATORY FAILURE	21	9	19.26	5.14	2.36	11.23
SYRINGE ISSUE	52	32	35.48	3.58	2.31	5.56
BLOOD GLUCOSE INCREASED	16	6	15.79	5.88	2.30	15.02
OLIGOMENORRHOEA	16	6	15.79	5.88	2.30	15.02
HYPERTENSION	88	61	52.65	3.18	2.29	4.41
CONDITION AGGRAVATED	379	316	176.73	2.64	2.28	3.07
VACCINATION SITE PAIN	108	78	61.39	3.05	2.28	4.08
NERVOUSNESS	137	104	72.83	2.90	2.25	3.74
BLOOD GLUCOSE DECREASED	14	5	14.05	6.17	2.22	17.13
MUSCULOSKELETAL CHEST PAIN	60	41	36.15	3.23	2.17	4.80
OXYGEN SATURATION DECREASED	55	37	33.71	3.28	2.16	4.97
VACCINATION SITE RASH	18	8	15.78	4.96	2.16	11.40
LYMPH NODE PAIN	76	55	42.68	3.05	2.15	4.31
PLEURAL EFFUSION	26	14	19.74	4.09	2.14	7.84
CARDIOMEGALY	15	6	14.01	5.51	2.14	14.20
HEART RATE IRREGULAR	41	26	26.70	3.48	2.13	5.68
BREATH SOUNDS ABNORMAL	36	22	24.33	3.61	2.12	6.13
CHILLS	946	902	351.95	2.31	2.11	2.53
DEAFNESS	69	50	38.55	3.04	2.11	4.38
SEIZURE	500	464	193.28	2.37	2.10	2.69
CARDIAC ARREST	24	13	17.99	4.07	2.07	7.99
POLYMENORRHOEA	16	7	14.03	5.04	2.07	12.24
IMMUNOGLOBULIN THERAPY	185	160	80.07	2.55	2.06	3.15
EPISTAXIS	133	112	59.90	2.62	2.04	3.36
IMMUNODEFICIENCY	13	5	12.26	5.73	2.04	16.07
MENSTRUATION IRREGULAR	88	70	43.08	2.77	2.03	3.79
RHINOVIRUS INFECTION	10	3	10.61	7.35	2.02	26.69
THROAT TIGHTNESS	208	189	82.44	2.43	1.99	2.95
HEART RATE DECREASED	118	100	52.43	2.60	1.99	3.39
GAIT INABILITY	52	38	28.40	3.02	1.99	4.58
BREAST PAIN	11	4	10.51	6.06	1.93	19.03
PANCREATITIS ACUTE	11	4	10.51	6.06	1.93	19.03
MENSTRUATION DELAYED	26	16	17.04	3.58	1.92	6.67
NASAL CONGESTION	168	156	63.63	2.37	1.91	2.95
LIP DISCOLOURATION	16	8	12.45	4.41	1.89	10.30
INCORRECT PRODUCT FORMULATION ADMINISTERED	97	85	40.43	2.52	1.88	3.36
EXTRA DOSE ADMINISTERED	335	339	107.52	2.18	1.87	2.53
FEEDING DISORDER	32	23	17.41	3.07	1.79	5.24
HEPATIC STEATOSIS	9	3	8.78	6.61	1.79	24.42
FACIAL PARALYSIS	56	48	23.81	2.57	1.75	3.78
HYPOXIA	30	22	15.78	3.01	1.73	5.21
CARDIAC FAILURE	10	4	8.76	5.51	1.73	17.57
ELECTROCARDIOGRAM QT PROLONGED	10	4	8.76	5.51	1.73	17.57
ORTHOPNOEA	10	4	8.76	5.51	1.73	17.57
BLINDNESS	106	105	34.80	2.22	1.70	2.91
INFLAMMATION	76	72	27.09	2.33	1.69	3.21
TRANSFUSION	20	13	11.95	3.39	1.69	6.81
ELECTROCARDIOGRAM AMBULATORY	11	5	8.83	4.85	1.68	13.95
EAR DISCOMFORT	32	25	15.37	2.82	1.67	4.76
TINNITUS	181	197	48.43	2.02	1.66	2.48
VACCINATION FAILURE	41	35	17.27	2.58	1.64	4.05
SUPRAVENTRICULAR TACHYCARDIA	15	9	9.54	3.67	1.61	8.39
DRY THROAT	17	11	10.02	3.41	1.60	7.27
SEPSIS	16	10	9.77	3.53	1.60	7.77
RHABDOMYOLYSIS	18	12	10.28	3.31	1.59	6.86
LIMB DISCOMFORT	85	88	25.11	2.13	1.58	2.87
LIP ERYTHEMA	8	3	7.00	5.88	1.56	22.15
TONGUE PRURITUS	8	3	7.00	5.88	1.56	22.15
HYPOPNOEA	29	24	12.58	2.66	1.55	4.57
CARDIOVERSION	9	4	7.07	4.96	1.53	16.10
PHARYNGEAL PARAESTHESIA	9	4	7.07	4.96	1.53	16.10
ABDOMINAL PAIN LOWER	40	38	13.73	2.32	1.49	3.62
TESTICULAR PAIN	15	10	8.36	3.31	1.49	7.36
ATELECTASIS	12	7	7.61	3.78	1.49	9.60
PLATELET COUNT DECREASED	12	7	7.61	3.78	1.49	9.60
BLOOD PRESSURE SYSTOLIC DECREASED	11	6	7.39	4.04	1.49	10.92
HYPOACUSIS	69	74	18.59	2.06	1.48	2.85
PANCYTOPENIA	14	9	8.09	3.43	1.48	7.92
PROTEINURIA	13	8	7.84	3.58	1.48	8.64
CONJUNCTIVITIS	23	19	9.79	2.67	1.45	4.90
DEEP VEIN THROMBOSIS	19	15	8.53	2.79	1.42	5.49
ARRHYTHMIA	22	19	8.61	2.55	1.38	4.71
INJECTION SITE BRUISING	35	36	10.00	2.14	1.35	3.41
BLOOD PRESSURE FLUCTUATION	12	8	6.44	3.31	1.35	8.09
BRAIN OEDEMA	10	6	5.91	3.67	1.34	10.11
CHAPPED LIPS	9	5	5.68	3.97	1.33	11.84
REFUSAL OF TREATMENT BY PATIENT	9	5	5.68	3.97	1.33	11.84
SUICIDE ATTEMPT	9	5	5.68	3.97	1.33	11.84
BREAST SWELLING	8	4	5.47	4.41	1.33	14.64
HEPATITIS	8	4	5.47	4.41	1.33	14.64
APRAXIA	7	3	5.32	5.14	1.33	19.88
CARDIAC MONITORING	7	3	5.32	5.14	1.33	19.88
CARDIOGENIC SHOCK	7	3	5.32	5.14	1.33	19.88
HAEMORRHAGE INTRACRANIAL	7	3	5.32	5.14	1.33	19.88
HYPOALBUMINAEMIA	7	3	5.32	5.14	1.33	19.88
SEPTIC SHOCK	7	3	5.32	5.14	1.33	19.88
PULMONARY OEDEMA	15	12	6.36	2.75	1.29	5.88
FEAR	32	34	8.39	2.07	1.28	3.36
RESPIRATION ABNORMAL	26	26	7.70	2.20	1.28	3.79
SNEEZING	33	36	8.12	2.02	1.26	3.24
AXILLARY MASS	17	15	6.18	2.50	1.25	5.00
VACCINATION ERROR	17	15	6.18	2.50	1.25	5.00
AUTOPSY	12	9	5.43	2.94	1.24	6.97
CHROMATURIA	21	21	6.06	2.20	1.20	4.03
FLUID REPLACEMENT	9	6	4.53	3.31	1.18	9.29
ORAL PAIN	19	19	5.41	2.20	1.17	4.16
COSTOCHONDRITIS	21	22	5.43	2.10	1.16	3.82
LIMB INJURY	16	15	5.10	2.35	1.16	4.75
VAGINAL HAEMORRHAGE	18	19	4.46	2.09	1.10	3.98
BODY TEMPERATURE DECREASED	15	15	4.10	2.20	1.08	4.51
SKIN BURNING SENSATION	15	15	4.10	2.20	1.08	4.51
FEELING HOT	337	368	90.52	2.02	1.74	2.34
SENSATION OF FOREIGN BODY	28	30	7.10	2.06	1.23	3.44
OBESITY	21	21	6.06	2.20	1.20	4.03
TROPONIN INCREASED	132	1	284.13	290.92	40.68	2080.49
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	124	2	262.38	136.64	33.80	552.43
BELL'S PALSY	76	2	156.44	83.75	20.57	340.96
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	52	1	107.48	114.60	15.84	828.94
ANOSMIA	57	2	114.60	62.81	15.34	257.25
BLOOD PRESSURE SYSTOLIC INCREASED	42	1	85.45	92.57	12.74	672.51
DRUG INEFFECTIVE	42	1	85.45	92.57	12.74	672.51
VENTRICULAR TACHYCARDIA	41	2	79.48	45.18	10.93	186.77
POOR QUALITY PRODUCT ADMINISTERED	36	1	72.26	79.34	10.88	578.65
TROPONIN I INCREASED	36	1	72.26	79.34	10.88	578.65
MITRAL VALVE INCOMPETENCE	33	1	65.66	72.73	9.95	531.73
EXPOSURE TO SARS-COV-2	33	2	61.98	36.36	8.73	151.53
VACCINE BREAKTHROUGH INFECTION	27	1	52.49	59.51	8.09	437.88
EPINEPHRINE	26	1	50.30	57.30	7.78	422.24
COVID-19 IMMUNISATION	24	1	45.92	52.89	7.16	390.96
TASTE DISORDER	27	2	48.92	29.75	7.08	125.11
GENITAL ULCERATION	21	1	39.36	46.28	6.23	344.05
BLOOD PRESSURE DIASTOLIC INCREASED	19	1	35.00	41.87	5.61	312.78
VULVAL ULCERATION	21	2	35.95	23.14	5.43	98.68
VULVOVAGINAL PAIN	20	2	33.80	22.04	5.15	94.28
BLOOD PRESSURE DIASTOLIC DECREASED	14	1	24.15	30.86	4.06	234.63
GENERAL PHYSICAL CONDITION ABNORMAL	14	1	24.15	30.86	4.06	234.63
ELECTROCARDIOGRAM ABNORMAL	14	2	21.07	15.43	3.51	67.87
C-REACTIVE PROTEIN INCREASED	13	2	18.98	14.33	3.23	63.48
SEDATION	10	1	15.59	22.04	2.82	172.16
APPENDICITIS PERFORATED	9	1	13.48	19.84	2.51	156.55
GENITAL PAIN	9	1	13.48	19.84	2.51	156.55
PULMONARY VALVE INCOMPETENCE	9	1	13.48	19.84	2.51	156.55
ISCHAEMIC STROKE	10	2	12.86	11.02	2.41	50.29
ASPARTATE AMINOTRANSFERASE INCREASED	8	1	11.39	17.63	2.21	140.96
ELECTRIC SHOCK SENSATION	8	1	11.39	17.63	2.21	140.96
BLOOD PRESSURE MEASUREMENT	9	2	10.87	9.92	2.14	45.90
BUNDLE BRANCH BLOCK RIGHT	9	2	10.87	9.92	2.14	45.90
SYSTOLIC DYSFUNCTION	7	1	9.33	15.43	1.90	125.38
VITAL SIGNS MEASUREMENT	7	1	9.33	15.43	1.90	125.38
VULVOVAGINAL SWELLING	8	2	8.93	8.82	1.87	41.51
EAR PRURITUS	7	2	7.05	7.71	1.60	37.13
HYPOMENORRHOEA	7	2	7.05	7.71	1.60	37.13
RED BLOOD CELL SEDIMENTATION RATE INCREASED	7	2	7.05	7.71	1.60	37.13
ANTIBIOTIC THERAPY	6	1	7.31	13.22	1.59	109.83
IGA NEPHROPATHY	6	1	7.31	13.22	1.59	109.83
SLEEP TERROR	6	1	7.31	13.22	1.59	109.83
THROMBOLYSIS	6	1	7.31	13.22	1.59	109.83
EYE HAEMORRHAGE	6	2	5.25	6.61	1.33	32.76
SOLILOQUY	6	2	5.25	6.61	1.33	32.76
ABDOMINAL LYMPHADENOPATHY	5	1	5.36	11.02	1.29	94.32
BEHAVIOUR DISORDER	5	1	5.36	11.02	1.29	94.32
CEREBRAL VENOUS SINUS THROMBOSIS	5	1	5.36	11.02	1.29	94.32
KAWASAKI'S DISEASE	5	1	5.36	11.02	1.29	94.32
OTORRHOEA	5	1	5.36	11.02	1.29	94.32
PNEUMONITIS	5	1	5.36	11.02	1.29	94.32
THROMBOTIC THROMBOCYTOPENIC PURPURA	5	1	5.36	11.02	1.29	94.32
VENTRICULAR FIBRILLATION	5	1	5.36	11.02	1.29	94.32

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• AGES 18+ YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• AGES 18+ YEARS excludes missing ages

MedDRA Codes ALL Reports (18+)	12/14/2020-03/18/2022 COVID19 mRNA N=618096	01/01/2009-03/18/2022 NON-COVID19 N=282143	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
COVID-19 PNEUMONIA	4021	9	1820.16	203.94	106.04	392.24
COVID-19	33319	138	15445.40	110.21	93.25	130.26
EXPOSURE TO SARS-COV-2	1779	4	802.42	203.02	76.11	541.51
VACCINE BREAKTHROUGH INFECTION	3267	14	1461.07	106.52	63.02	180.06
ASYMPTOMATIC COVID-19	958	3	428.99	145.77	46.93	452.76
LUNG OPACITY	1606	8	713.47	91.64	45.75	183.55
HEAVY MENSTRUAL BLEEDING	4144	30	1825.97	63.05	44.03	90.30
VACCINATION SITE PRURITUS	3933	29	1731.25	61.91	42.96	89.20
SARS-COV-2 TEST POSITIVE	869	3	388.29	132.22	42.56	410.77
POOR QUALITY PRODUCT ADMINISTERED	920	4	409.19	104.99	39.32	280.32
INTERMENSTRUAL BLEEDING	1292	8	569.73	73.72	36.79	147.73
PRODUCT DOSE OMISSION ISSUE	1692	13	740.86	59.41	34.43	102.53
INTERCHANGE OF VACCINE PRODUCTS	8227	94	3560.92	39.95	32.60	48.96
DYSMENORRHOEA	1778	25	751.92	32.46	21.88	48.18
PULMONARY THROMBOSIS	574	5	248.68	52.40	21.73	126.38
POSTMENOPAUSAL HAEMORRHAGE	505	4	219.54	57.63	21.55	154.14
POLYMENORRHOEA	678	7	291.44	44.21	21.00	93.09
POSITIVE AIRWAY PRESSURE THERAPY	658	7	282.31	42.91	20.38	90.36
MENSTRUATION IRREGULAR	3149	59	1300.80	24.36	18.83	31.52
SUSPECTED COVID-19	495	5	212.61	45.19	18.73	109.05
MENSTRUAL DISORDER	2409	44	996.56	24.99	18.55	33.67
ANOSMIA	3424	69	1403.88	22.65	17.85	28.75
ILLNESS	4113	85	1683.15	22.09	17.82	27.38
PRODUCT TEMPERATURE EXCURSION ISSUE	573	7	243.51	37.37	17.73	78.73
OLIGOMENORRHOEA	542	7	229.37	35.34	16.77	74.49
ANTICOAGULANT THERAPY	3320	83	1324.67	18.26	14.69	22.70
POST-ACUTE COVID-19 SYNDROME	292	3	124.70	44.43	14.25	138.56
TASTE DISORDER	2055	57	805.74	16.46	12.65	21.41
THROMBECTOMY	317	5	131.45	28.94	11.96	70.01
VACCINATION SITE URTICARIA	318	6	129.62	24.19	10.79	54.26
MATERNAL EXPOSURE DURING BREAST FEEDING	286	5	117.33	26.11	10.79	63.21
MECHANICAL URTICARIA	756	21	295.07	16.43	10.65	25.35
DRUG INEFFECTIVE	1239	40	472.48	14.14	10.32	19.37
IMMUNISATION	2723	99	1017.82	12.56	10.27	15.34
BELL'S PALSY	3090	114	1152.12	12.37	10.26	14.92
VACCINATION SITE MASS	1159	38	440.59	13.92	10.08	19.23
VACCINATION SITE ERYTHEMA	6111	246	2244.01	11.34	9.98	12.88
MENSTRUATION DELAYED	1073	37	403.83	13.24	9.54	18.37
AGEUSIA	4276	178	1554.10	10.97	9.44	12.74
APPENDICITIS	615	19	235.55	14.78	9.36	23.32
THROMBOSIS	3029	125	1101.20	11.06	9.25	13.23
PULMONARY EMBOLISM	2915	132	1035.18	10.08	8.47	12.00
THROAT CLEARING	398	13	150.41	13.98	8.04	24.28
PRODUCT USE ISSUE	454	16	169.26	12.95	7.87	21.32
EPINEPHRINE	386	13	144.99	13.55	7.80	23.55
ELECTRIC SHOCK SENSATION	792	33	285.59	10.96	7.73	15.52
PAROSMIA	1280	60	448.80	9.74	7.52	12.62
OFF LABEL USE	1165	55	407.51	9.67	7.38	12.67
BLOOD PRESSURE DIASTOLIC INCREASED	217	6	83.76	16.51	7.34	37.15
VACCINATION SITE MOVEMENT IMPAIRMENT	341	12	126.83	12.97	7.29	23.07
VITAL SIGNS MEASUREMENT	149	3	59.57	22.67	7.23	71.09
FACIAL DISCOMFORT	311	11	115.43	12.91	7.07	23.55
CARDIAC FLUTTER	1247	66	421.90	8.62	6.73	11.05
LEFT VENTRICULAR FAILURE	196	6	74.26	14.91	6.62	33.60
OROPHARYNGEAL DISCOMFORT	1471	82	489.79	8.19	6.56	10.23
BLOOD PRESSURE MEASUREMENT	193	6	72.91	14.68	6.52	33.09
DEATH	8445	617	2559.10	6.25	5.76	6.78
SYMPTOM RECURRENCE	119	3	45.97	18.11	5.76	56.94
DEEP VEIN THROMBOSIS	2078	139	648.03	6.82	5.75	8.10
THERAPEUTIC RESPONSE UNEXPECTED	486	26	162.99	8.53	5.75	12.66
INFUSION	170	6	62.53	12.93	5.73	29.19
PHARYNGEAL PARAESTHESIA	935	58	299.21	7.36	5.64	9.59
DEVICE CONNECTION ISSUE	342	17	116.91	9.18	5.64	14.95
PHARYNGEAL SWELLING	4276	310	1293.19	6.30	5.61	7.07
HYPERVOLAEMIA	183	7	66.27	11.93	5.61	25.39
SUPPRESSED LACTATION	131	4	49.22	14.95	5.53	40.43
ACCIDENTAL OVERDOSE	274	13	94.66	9.62	5.52	16.78
PREMENSTRUAL SYNDROME	145	5	53.40	13.24	5.43	32.28
VACCINATION SITE PAIN	14096	1120	4135.06	5.75	5.41	6.10
VACCINATION SITE RASH	2493	187	740.33	6.09	5.25	7.06
BLOOD LOSS ANAEMIA	137	5	49.80	12.51	5.12	30.53
CARDIAC FAILURE ACUTE	263	14	87.76	8.58	5.01	14.68
APPENDICECTOMY	460	29	145.63	7.24	4.98	10.54
OPHTHALMIC MIGRAINE	103	3	38.73	15.67	4.97	49.39
HYPOMENORRHOEA	161	7	56.41	10.50	4.93	22.38
CARDIAC DISCOMFORT	324	19	104.96	7.78	4.90	12.36
CHRONIC SPONTANEOUS URTICARIA	130	5	46.65	11.87	4.86	28.99
STENT PLACEMENT	276	16	89.59	7.87	4.76	13.03
IMMUNE THROMBOCYTOPENIA	337	21	106.83	7.33	4.71	11.38
TONGUE DISCOMFORT	589	42	177.66	6.40	4.68	8.75
PRODUCT PREPARATION ISSUE	2269	194	630.83	5.34	4.61	6.18
GENERAL PHYSICAL CONDITION ABNORMAL	287	18	90.58	7.28	4.52	11.72
PULMONARY INFARCTION	121	5	42.62	11.05	4.52	27.02
BREAST FEEDING	107	4	38.41	12.21	4.50	33.13
ACUTE RESPIRATORY FAILURE	3178	290	853.20	5.00	4.44	5.64
END STAGE RENAL DISEASE	144	7	48.82	9.39	4.40	20.05
ACUTE LEFT VENTRICULAR FAILURE	118	5	41.27	10.77	4.40	26.36
BODY TEMPERATURE ABNORMAL	169	9	55.95	8.57	4.38	16.76
TONGUE PRURITUS	495	38	144.16	5.95	4.28	8.27
TINNITUS	12721	1284	3249.24	4.52	4.27	4.79
BLOOD PRESSURE SYSTOLIC INCREASED	476	37	137.75	5.87	4.20	8.21
HEART RATE	125	6	42.37	9.51	4.19	21.57
HYPERAESTHESIA TEETH	149	8	49.05	8.50	4.17	17.31
ISCHAEMIC STROKE	460	36	132.64	5.83	4.15	8.19
DRAINAGE	202	13	62.77	7.09	4.05	12.43
ENERGY INCREASED	168	10	53.55	7.67	4.05	14.51
CORONARY ARTERIAL STENT INSERTION	244	17	73.64	6.55	4.01	10.71
TROPONIN INCREASED	360	28	103.87	5.87	4.00	8.62
CEREBROVASCULAR ACCIDENT	2889	294	724.27	4.49	3.98	5.06
SITTING DISABILITY	142	8	45.96	8.10	3.97	16.52
HOSPICE CARE	219	15	66.45	6.66	3.95	11.24
SUPERINFECTION	82	3	29.28	12.48	3.94	39.49
OXYGEN SATURATION DECREASED	2710	284	665.79	4.36	3.85	4.92
AMENORRHOEA	656	60	174.50	4.99	3.83	6.50
ACUTE MYOCARDIAL INFARCTION	1281	128	323.82	4.57	3.81	5.48
CHRONIC LEFT VENTRICULAR FAILURE	125	7	40.39	8.15	3.81	17.45
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	260	20	75.09	5.93	3.77	9.35
IMMUNODEFICIENCY	578	53	153.38	4.98	3.76	6.59
HYPOXIA	3423	376	814.25	4.16	3.74	4.62
PULMONARY PAIN	477	43	127.64	5.06	3.71	6.92
CORONARY ARTERY OCCLUSION	185	13	55.35	6.50	3.70	11.40
DYSPNOEA AT REST	88	4	29.91	10.04	3.69	27.35
VACCINATION SITE DISCOMFORT	283	23	79.64	5.62	3.67	8.59
VENTRICULAR HYPOKINESIA	142	9	44.04	7.20	3.67	14.13
BREAST MASS	396	35	106.97	5.16	3.66	7.30
HAEMORRHAGE URINARY TRACT	131	8	41.11	7.47	3.66	15.26
CEREBRAL INFARCTION	396	36	105.26	5.02	3.57	7.06
AUTOPSY	322	28	87.56	5.25	3.57	7.72
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	8882	1072	1978.48	3.78	3.55	4.03
EXTRASYSTOLES	553	54	141.16	4.67	3.54	6.18
CLUSTER HEADACHE	126	8	38.92	7.19	3.52	14.69
PRODUCT STORAGE ERROR	13555	1675	2978.41	3.69	3.51	3.89
HEART RATE ABNORMAL	468	45	120.45	4.75	3.50	6.45
PERCUTANEOUS CORONARY INTERVENTION	73	3	25.25	11.11	3.50	35.24
LUNG INFILTRATION	1004	108	241.04	4.24	3.48	5.17
CARDIAC FAILURE	578	58	145.02	4.55	3.47	5.96
VACCINATION SITE HAEMORRHAGE	229	19	63.55	5.50	3.45	8.78
OXYGEN SATURATION	93	5	30.15	8.49	3.45	20.88
HEAD DISCOMFORT	2846	340	633.82	3.82	3.41	4.28
LUNG CONSOLIDATION	298	27	79.09	5.04	3.40	7.47
MENOPAUSE	122	8	37.17	6.96	3.40	14.23
GENERAL PHYSICAL HEALTH DETERIORATION	876	96	207.34	4.17	3.37	5.14
NEAR DEATH EXPERIENCE	140	10	41.31	6.39	3.36	12.14
MYOCARDIAL INFARCTION	1479	172	335.52	3.93	3.35	4.60
PULSELESS ELECTRICAL ACTIVITY	294	27	77.40	4.97	3.35	7.37
HOSPITALISATION	149	11	43.39	6.18	3.35	11.41
BLOOD GLUCOSE DECREASED	309	29	80.35	4.86	3.32	7.12
FIBRIN D DIMER INCREASED	138	10	40.44	6.30	3.32	11.97
APPENDICITIS PERFORATED	109	7	33.36	7.11	3.31	15.26
PERIORBITAL SWELLING	691	76	162.87	4.15	3.28	5.26
PNEUMONIA VIRAL	155	12	44.18	5.90	3.28	10.61
BLOOD PRESSURE DIASTOLIC DECREASED	108	7	32.92	7.04	3.28	15.13
EUPHORIC MOOD	260	24	68.11	4.95	3.26	7.51
CARDIAC ASSISTANCE DEVICE USER	78	4	25.47	8.90	3.26	24.31
ANGINA PECTORIS	1006	117	227.76	3.92	3.24	4.75
RESPIRATORY RATE DECREASED	293	28	75.29	4.78	3.24	7.04
PERICARDIAL EFFUSION	738	83	171.15	4.06	3.23	5.09
MULTIPLE ORGAN DYSFUNCTION SYNDROME	241	22	63.47	5.00	3.23	7.74
PARANASAL SINUS DISCOMFORT	843	97	192.27	3.97	3.22	4.89
EMBOLIC STROKE	87	5	27.50	7.94	3.22	19.56
BRADYKINESIA	170	14	47.07	5.54	3.21	9.56
CARDIO-RESPIRATORY ARREST	597	66	140.03	4.13	3.20	5.32
CARDIAC ARREST	1453	178	315.90	3.73	3.19	4.35
MYOCARDITIS	1905	240	404.84	3.62	3.17	4.14
ADNEXA UTERI PAIN	132	10	37.85	6.03	3.17	11.46
DEMENTIA	396	42	95.35	4.30	3.13	5.92
BREAST SWELLING	724	85	162.37	3.89	3.11	4.87
ATYPICAL PNEUMONIA	120	9	34.47	6.09	3.09	11.98
PNEUMONIA BACTERIAL	309	32	75.41	4.41	3.06	6.34
SENSITIVE SKIN	1247	158	263.15	3.60	3.05	4.25
BREAST TENDERNESS	515	59	117.43	3.98	3.04	5.22
VACCINATION SITE DISCOLOURATION	330	35	79.28	4.30	3.04	6.10
BLOOD DISORDER	73	4	23.26	8.33	3.04	22.79
GIANT CELL ARTERITIS	63	3	20.80	9.59	3.01	30.52
EXPIRED PRODUCT ADMINISTERED	13906	2018	2624.54	3.15	3.00	3.30
CHRONIC KIDNEY DISEASE	530	62	118.91	3.90	3.00	5.08
HAEMOGLOBIN DECREASED	99	7	29.01	6.46	3.00	13.89
ACUTE KIDNEY INJURY	2324	315	462.24	3.37	2.99	3.79
CARDIOGENIC SHOCK	230	23	57.19	4.56	2.97	7.01
LYMPHADENOPATHY	21469	3194	3984.59	3.07	2.96	3.18
VENTRICULAR EXTRASYSTOLES	952	124	195.68	3.50	2.91	4.23
CEREBRAL HAEMORRHAGE	398	46	89.90	3.95	2.91	5.36
EAR DISCOMFORT	2537	359	483.68	3.23	2.89	3.60
BLOOD PRESSURE ABNORMAL	521	64	112.27	3.72	2.87	4.82
OCULAR DISCOMFORT	855	112	174.71	3.48	2.86	4.24
BLOOD PRESSURE SYSTOLIC DECREASED	86	6	25.20	6.54	2.86	14.97
SINUS RHYTHM	60	3	19.47	9.13	2.86	29.11
PERICARDITIS	1582	220	306.26	3.28	2.85	3.78
CARDIAC ABLATION	135	12	35.63	5.14	2.85	9.27
PALPITATIONS	14184	2190	2500.77	2.96	2.83	3.09
IMPAIRED SELF-CARE	85	6	24.76	6.47	2.83	14.80
RETINAL VEIN OCCLUSION	93	7	26.42	6.06	2.81	13.07
CARDIAC DISORDER	849	114	169.50	3.40	2.80	4.13
ATRIAL FIBRILLATION	3305	498	590.02	3.03	2.76	3.33
HYPERTENSIVE EMERGENCY	83	6	23.90	6.31	2.76	14.46
CORONARY ARTERY THROMBOSIS	57	3	18.14	8.67	2.72	27.69
LYMPH NODE PAIN	5200	815	889.93	2.91	2.71	3.14
SWELLING OF EYELID	1096	157	205.46	3.19	2.70	3.77
EJECTION FRACTION DECREASED	194	21	45.52	4.22	2.69	6.61
ATRIOVENTRICULAR BLOCK COMPLETE	81	6	23.04	6.16	2.69	14.12
TONGUE ERYTHEMA	135	13	33.96	4.74	2.68	8.37
UTERINE PAIN	56	3	17.70	8.52	2.67	27.22
RETINAL ARTERY OCCLUSION	96	8	25.94	5.48	2.66	11.27
EPISTAXIS	1956	298	343.94	3.00	2.65	3.38
PLATELET COUNT DECREASED	282	34	61.27	3.79	2.65	5.40
EYE HAEMORRHAGE	287	35	61.78	3.74	2.64	5.32
RESPIRATORY RATE INCREASED	1364	204	244.42	3.05	2.63	3.54
RESUSCITATION	1009	148	184.38	3.11	2.62	3.70
GASTROINTESTINAL WALL THICKENING	55	3	17.26	8.37	2.62	26.75
DYSPNOEA EXERTIONAL	2024	314	348.62	2.94	2.61	3.31
PULSE ABSENT	604	84	116.23	3.28	2.61	4.12
BLOOD URINE PRESENT	590	82	113.58	3.28	2.61	4.14
SLEEP DEFICIT	94	8	25.09	5.36	2.61	11.04
MIGRAINE	7986	1322	1282.96	2.76	2.60	2.92
VEIN DISORDER	131	13	32.29	4.60	2.60	8.13
LUNG DISORDER	567	79	108.85	3.28	2.59	4.15
ARRHYTHMIA	1082	162	193.41	3.05	2.58	3.60
DISORGANISED SPEECH	130	13	31.88	4.56	2.58	8.07
BREAST DISCOMFORT	115	11	28.90	4.77	2.57	8.86
BREAST DISCHARGE	62	4	18.45	7.08	2.57	19.45
LYMPHADENOPATHY MEDIASTINAL	107	10	27.20	4.88	2.55	9.34
GENERAL SYMPTOM	135	14	32.34	4.40	2.54	7.63
INJECTION SITE LYMPHADENOPATHY	121	12	29.76	4.60	2.54	8.33
HEART RATE IRREGULAR	1922	308	318.41	2.85	2.53	3.21
VAGINAL HAEMORRHAGE	1515	238	256.75	2.91	2.53	3.33
THALAMIC INFARCTION	61	4	18.01	6.96	2.53	19.14
CARDIOVERSION	483	68	91.61	3.24	2.52	4.18
DEMENTIA ALZHEIMER'S TYPE	120	12	29.35	4.56	2.52	8.26
HORMONE LEVEL ABNORMAL	98	9	25.09	4.97	2.51	9.84
VACCINATION SITE INDURATION	1183	185	201.30	2.92	2.50	3.41
CARDIOMEGALY	785	118	139.42	3.04	2.50	3.68
FEAR OF INJECTION	227	28	48.20	3.70	2.50	5.48
BREAST CYST	68	5	19.23	6.21	2.50	15.39
PANIC ATTACK	1206	190	203.44	2.90	2.49	3.38
SUDDEN DEATH	158	18	35.49	4.01	2.46	6.52
HEART RATE DECREASED	1368	221	224.00	2.83	2.45	3.26
PHARYNGEAL HYPOAESTHESIA	465	67	86.07	3.17	2.45	4.09
BONE SWELLING	59	4	17.14	6.73	2.45	18.53
NEW DAILY PERSISTENT HEADACHE	59	4	17.14	6.73	2.45	18.53
HOT FLUSH	3413	585	520.23	2.66	2.44	2.91
URTICARIA CHRONIC	156	18	34.68	3.96	2.43	6.44
HYPERTENSIVE URGENCY	109	11	26.40	4.52	2.43	8.41
IMPAIRED QUALITY OF LIFE	102	10	25.12	4.66	2.43	8.91
NEOPLASM	88	8	22.56	5.02	2.43	10.35
CHEST PAIN	20468	3734	2925.75	2.50	2.42	2.59
PARAESTHESIA ORAL	6402	1136	934.44	2.57	2.42	2.74
PRODUCT ADMINISTRATION ERROR	684	105	118.50	2.97	2.42	3.65
THROMBOPHLEBITIS SUPERFICIAL	142	16	32.07	4.05	2.42	6.79
HEPATIC LESION	58	4	16.71	6.62	2.40	18.23
HILAR LYMPHADENOPATHY	58	4	16.71	6.62	2.40	18.23
BLOOD GLUCOSE INCREASED	832	132	138.86	2.88	2.39	3.46
BREAST ENLARGEMENT	65	5	17.94	5.93	2.39	14.74
VENTRICULAR FIBRILLATION	229	30	46.09	3.48	2.38	5.10
ACUTE CORONARY SYNDROME	79	7	20.45	5.15	2.38	11.16
VACCINATION SITE WARMTH	3259	576	476.02	2.58	2.36	2.82
SKIN SENSITISATION	171	21	36.21	3.72	2.36	5.85
MOUTH SWELLING	924	151	148.80	2.79	2.35	3.32
PULMONARY MASS	441	66	78.30	3.05	2.35	3.95
PULMONARY OEDEMA	722	116	118.54	2.84	2.34	3.46
DIVERTICULITIS	274	38	52.37	3.29	2.34	4.62
CONDITION AGGRAVATED	16496	3130	2208.41	2.41	2.32	2.50
VACCINATION SITE SWELLING	5152	948	711.76	2.48	2.32	2.66
BREAST PAIN	1895	332	279.40	2.61	2.32	2.93
JUGULAR VEIN DISTENSION	56	4	15.85	6.39	2.32	17.62
THROMBOLYSIS	56	4	15.85	6.39	2.32	17.62
BLOOD IRON DECREASED	49	3	14.64	7.46	2.32	23.92
VACCINATION SITE REACTION	1252	214	190.52	2.67	2.31	3.09
NIPPLE PAIN	116	13	26.13	4.07	2.30	7.23
FEEDING DISORDER	1379	242	202.51	2.60	2.27	2.98
DISCOLOURED VOMIT	48	3	14.20	7.30	2.27	23.45
HEART RATE INCREASED	13572	2626	1753.81	2.36	2.26	2.46
SEIZURE	3673	683	498.20	2.45	2.26	2.66
PERICARDIAL DRAINAGE	88	9	20.93	4.46	2.25	8.86
MENTAL FATIGUE	75	7	18.77	4.89	2.25	10.61
UTERINE SPASM	126	15	27.13	3.83	2.24	6.55
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION	61	5	16.24	5.57	2.24	13.86
HAEMORRHAGIC STROKE	113	13	24.92	3.97	2.23	7.04
DIZZINESS EXERTIONAL	47	3	13.77	7.15	2.23	22.98
FEAR	793	136	119.77	2.66	2.22	3.19
NONINFECTIVE GINGIVITIS	87	9	20.52	4.41	2.22	8.76
INCORRECT PRODUCT FORMULATION ADMINISTERED	709	121	107.70	2.67	2.21	3.24
PALLIATIVE CARE	80	8	19.23	4.56	2.21	9.44
VERTIGO	7405	1451	929.08	2.33	2.20	2.46
SUPRAVENTRICULAR TACHYCARDIA	494	81	78.80	2.78	2.20	3.52
UNRESPONSIVE TO STIMULI	4105	792	525.71	2.37	2.19	2.55
TRANSIENT ISCHAEMIC ATTACK	724	125	108.28	2.64	2.19	3.20
VENTRICULAR TACHYCARDIA	362	57	60.47	2.90	2.19	3.83
NASAL DRYNESS	111	13	24.11	3.90	2.19	6.92
AUTOSCOPY	79	8	18.81	4.51	2.18	9.33
DYSGEUSIA	4104	804	512.52	2.33	2.16	2.51
LIP PRURITUS	368	59	60.15	2.85	2.16	3.75
SINUS PAIN	457	76	71.53	2.74	2.15	3.50
HEART VALVE INCOMPETENCE	65	6	16.24	4.95	2.14	11.41
MUSCLE DISCOMFORT	183	26	33.83	3.21	2.13	4.84
HYPERTENSION	7255	1477	852.10	2.24	2.12	2.37
IMPLANTABLE DEFIBRILLATOR INSERTION	77	8	17.99	4.39	2.12	9.10
FEELING ABNORMAL	21127	4426	2401.68	2.18	2.11	2.25
PLEURAL EFFUSION	1127	210	151.37	2.45	2.11	2.84
BLOOD PRESSURE FLUCTUATION	454	77	69.24	2.69	2.11	3.43
SUPRAVENTRICULAR EXTRASYSTOLES	252	39	42.70	2.95	2.11	4.13
RESPIRATORY SYMPTOM	300	48	49.01	2.85	2.10	3.87
ARTERIOSCLEROSIS CORONARY ARTERY	219	33	38.15	3.03	2.10	4.37
RENAL INFARCT	51	4	13.71	5.82	2.10	16.10
CROHN'S DISEASE	163	23	30.25	3.23	2.09	5.01
HEPATIC CIRRHOSIS	129	17	25.42	3.46	2.09	5.74
INCORRECT DOSE ADMINISTERED	4802	984	555.39	2.23	2.08	2.39
SKIN SWELLING	674	122	94.21	2.52	2.08	3.06
ASTHENOPIA	354	59	55.06	2.74	2.08	3.61
FATIGUE	94183	20429	11149.54	2.10	2.07	2.14
HYPOACUSIS	1331	257	169.13	2.36	2.07	2.70
RENAL PAIN	594	107	83.52	2.53	2.06	3.11
INCREASED APPETITE	87	10	18.98	3.97	2.06	7.64
PERIPHERAL ISCHAEMIA	50	4	13.28	5.71	2.06	15.80
CARDIAC FAILURE CONGESTIVE	1020	195	131.50	2.39	2.05	2.78
PNEUMONITIS	240	38	39.54	2.88	2.05	4.06
HYPOAESTHESIA ORAL	4612	964	514.24	2.18	2.04	2.34
INTERSTITIAL LUNG DISEASE	202	31	34.40	2.97	2.04	4.34
GAIT INABILITY	2291	470	263.19	2.23	2.02	2.46
ORAL DISCOMFORT	767	145	100.45	2.41	2.02	2.88
VACCINATION SITE BRUISING	508	92	70.75	2.52	2.02	3.15
LUNG HYPERINFLATION	49	4	12.86	5.59	2.02	15.49
MOVEMENT DISORDER	1714	347	201.28	2.25	2.01	2.53
ABNORMAL DREAMS	501	91	69.46	2.51	2.01	3.14
SUDDEN CARDIAC DEATH	61	6	14.58	4.64	2.01	10.73
APHASIA	1917	394	219.27	2.22	1.99	2.48
DIABETIC KETOACIDOSIS	171	26	29.30	3.00	1.99	4.54
METAMORPHOPSIA	139	20	25.15	3.17	1.99	5.07
ALOPECIA	1246	251	147.33	2.27	1.98	2.59
CHEST DISCOMFORT	15010	3348	1494.74	2.05	1.97	2.12
BLOOD PRESSURE INCREASED	7806	1719	789.99	2.07	1.97	2.18
SMALL INTESTINAL OBSTRUCTION	138	20	24.77	3.15	1.97	5.03
HYPERTENSIVE HEART DISEASE	189	30	30.87	2.88	1.96	4.23
TOXIC ENCEPHALOPATHY	99	13	19.36	3.48	1.95	6.20
VASCULAR PAIN	99	13	19.36	3.48	1.95	6.20
FACIAL PARALYSIS	2662	572	280.55	2.12	1.94	2.32
ACUTE RESPIRATORY DISTRESS SYNDROME	360	65	50.14	2.53	1.94	3.29
CORONARY ARTERY DISEASE	590	114	74.42	2.36	1.93	2.89
GASTROINTESTINAL HAEMORRHAGE	386	71	52.34	2.48	1.93	3.20
SINUS OPERATION	212	35	33.06	2.76	1.93	3.95
ASCITES	166	26	27.45	2.91	1.93	4.41
CARDIAC TAMPONADE	76	9	16.06	3.85	1.93	7.69
VASODILATATION	140	21	24.21	3.04	1.92	4.81
HUNGER	190	31	29.99	2.80	1.91	4.09
HYPOGEUSIA	139	21	23.84	3.02	1.91	4.78
THYROIDITIS	75	9	15.67	3.80	1.91	7.59
TACHYPNOEA	1220	256	133.95	2.18	1.90	2.49
SEDATION	203	34	31.03	2.73	1.90	3.92
HYPOAESTHESIA EYE	159	25	26.14	2.90	1.90	4.43
PSORIATIC ARTHROPATHY	91	12	17.66	3.46	1.90	6.32
DENTAL DISCOMFORT	52	5	12.46	4.75	1.90	11.88
DEAFNESS	1283	272	138.19	2.15	1.89	2.45
EAR SWELLING	503	98	62.48	2.34	1.89	2.91
DISCHARGE	96	13	18.20	3.37	1.89	6.02
CHEST INJURY	46	4	11.60	5.25	1.89	14.58
THYROIDITIS SUBACUTE	46	4	11.60	5.25	1.89	14.58
DIALYSIS	216	37	32.09	2.66	1.88	3.78
CARDITIS	74	9	15.27	3.75	1.88	7.50
CEREBRAL VENOUS THROMBOSIS	40	3	10.76	6.09	1.88	19.67
INSULIN THERAPY	40	3	10.76	6.09	1.88	19.67
RENAL IMPAIRMENT	338	63	44.82	2.45	1.87	3.20
SUBARACHNOID HAEMORRHAGE	176	29	27.38	2.77	1.87	4.10
SUBDURAL HAEMATOMA	136	21	22.72	2.96	1.87	4.68
HEPATIC PAIN	95	13	17.82	3.34	1.87	5.96
ARTERIAL OCCLUSIVE DISEASE	68	8	14.35	3.88	1.87	8.07
BREAST CANCER	51	5	12.05	4.66	1.86	11.67
SYSTOLIC DYSFUNCTION	51	5	12.05	4.66	1.86	11.67
VENTRICULAR HYPERTROPHY	51	5	12.05	4.66	1.86	11.67
DRY THROAT	816	171	89.55	2.18	1.85	2.57
COLITIS	292	54	39.09	2.47	1.85	3.30
BLADDER PAIN	89	12	16.88	3.39	1.85	6.19
LEFT ATRIAL ENLARGEMENT	73	9	14.87	3.70	1.85	7.40
PULMONARY FIBROSIS	173	29	26.30	2.72	1.84	4.04
NERVOUSNESS	2087	472	197.74	2.02	1.83	2.23
LYMPHOEDEMA	281	52	37.55	2.47	1.83	3.32
LACUNAR INFARCTION	98	14	17.61	3.20	1.83	5.59
HYPOOSMOLAR STATE	39	3	10.33	5.93	1.83	19.20
ABDOMINAL PAIN LOWER	859	184	90.44	2.13	1.82	2.50
RED BLOOD CELL SEDIMENTATION RATE INCREASED	50	5	11.64	4.56	1.82	11.45
VITREOUS FLOATERS	519	106	59.44	2.23	1.81	2.75
APHTHOUS ULCER	298	57	37.85	2.39	1.80	3.17
THYROID MASS	131	21	20.89	2.85	1.80	4.51
CORONARY ARTERY STENOSIS	71	9	14.09	3.60	1.80	7.20
MENOMETRORRHAGIA	44	4	10.76	5.02	1.80	13.97
COSTOCHONDRITIS	215	39	29.44	2.52	1.79	3.54
BRAIN INJURY	150	25	22.87	2.74	1.79	4.18
LUNG NEOPLASM MALIGNANT	86	12	15.73	3.27	1.79	5.98
SEPTIC SHOCK	492	102	54.80	2.20	1.78	2.72
GINGIVAL BLEEDING	259	49	33.38	2.41	1.78	3.27
ANGIOPLASTY	65	8	13.16	3.71	1.78	7.73
SPLENIC INFARCTION	49	5	11.23	4.47	1.78	11.23
VACCINATION SITE DISCHARGE	49	5	11.23	4.47	1.78	11.23
ARTERIOSCLEROSIS	460	95	51.55	2.21	1.77	2.76
ATRIAL FLUTTER	298	58	36.78	2.35	1.77	3.11
POLYURIA	249	47	32.18	2.42	1.77	3.30
LEFT VENTRICULAR DYSFUNCTION	185	33	25.86	2.56	1.77	3.71
OXYGEN SATURATION ABNORMAL	70	9	13.70	3.55	1.77	7.11
ANGINA UNSTABLE	54	6	11.73	4.11	1.77	9.55
HAEMATOCHEZIA	586	125	61.97	2.14	1.76	2.60
BOWEL MOVEMENT IRREGULARITY	216	40	28.67	2.46	1.76	3.45
HAEMORRHAGE INTRACRANIAL	124	20	19.58	2.83	1.76	4.54
ATRIAL ENLARGEMENT	43	4	10.35	4.91	1.76	13.67
ISCHAEMIC CEREBRAL INFARCTION	43	4	10.35	4.91	1.76	13.67
NEUROLOGICAL SYMPTOM	730	161	72.38	2.07	1.75	2.45
MUSCLE STRENGTH ABNORMAL	89	13	15.54	3.13	1.75	5.59
AXILLARY MASS	840	188	80.88	2.04	1.74	2.39
BLEPHAROSPASM	546	117	57.18	2.13	1.74	2.60
BODY TEMPERATURE FLUCTUATION	232	44	29.71	2.41	1.74	3.32
APPETITE DISORDER	113	18	18.05	2.87	1.74	4.71
POOR PERIPHERAL CIRCULATION	108	17	17.47	2.90	1.74	4.84
THERMAL BURN	103	16	16.89	2.94	1.74	4.98
CORONARY ANGIOPLASTY	37	3	9.49	5.63	1.74	18.26
IMMUNE-MEDIATED ADVERSE REACTION	37	3	9.49	5.63	1.74	18.26
TENSION HEADACHE	360	74	40.54	2.22	1.73	2.85
CHEST TUBE INSERTION	126	21	19.09	2.74	1.73	4.35
COMA SCALE ABNORMAL	98	15	16.31	2.98	1.73	5.14
BLOOD GLUCOSE ABNORMAL	88	13	15.17	3.09	1.73	5.53
IRREGULAR BREATHING	73	10	13.48	3.33	1.72	6.45
MYOCARDIAL OEDEMA	42	4	9.94	4.79	1.72	13.37
RIGHT VENTRICULAR FAILURE	42	4	9.94	4.79	1.72	13.37
GLOSSITIS	139	24	20.15	2.64	1.71	4.08
BASEDOW'S DISEASE	125	21	18.73	2.72	1.71	4.31
EYE CONTUSION	125	21	18.73	2.72	1.71	4.31
FOOD AVERSION	47	5	10.42	4.29	1.71	10.79
HYPERKALAEMIA	308	63	34.90	2.23	1.70	2.93
DISSOCIATION	133	23	19.21	2.64	1.70	4.11
ACUTE PULMONARY OEDEMA	57	7	11.45	3.72	1.70	8.15
BILIARY COLIC	52	6	10.93	3.96	1.70	9.21
FEELING DRUNK	335	70	36.56	2.18	1.69	2.83
EAR DISORDER	146	26	20.30	2.56	1.69	3.89
TESTICULAR PAIN	193	37	24.17	2.38	1.68	3.38
MOTION SICKNESS	189	36	23.91	2.40	1.68	3.42
HYPOTHERMIA	145	26	19.95	2.55	1.68	3.86
ISCHAEMIA	95	15	15.21	2.89	1.68	4.98
WHITE BLOOD CELL COUNT DECREASED	81	12	13.85	3.08	1.68	5.65
BLOOD THYROID STIMULATING HORMONE INCREASED	41	4	9.52	4.68	1.68	13.06
MUCOSAL DISORDER	41	4	9.52	4.68	1.68	13.06
EMBOLISM	66	9	12.16	3.35	1.67	6.72
AUTOIMMUNE HEPATITIS	51	6	10.53	3.88	1.67	9.04
INFLAMMATORY MARKER INCREASED	46	5	10.02	4.20	1.67	10.57
CARDIOMYOPATHY	342	73	35.85	2.14	1.66	2.75
AORTIC ANEURYSM	103	17	15.66	2.77	1.66	4.62
HYPOSMIA	94	15	14.85	2.86	1.66	4.93
STRESS CARDIOMYOPATHY	80	12	13.48	3.04	1.66	5.58
HAEMOPTYSIS	454	101	43.97	2.05	1.65	2.55
PREGNANCY	279	58	30.63	2.20	1.65	2.91
HORDEOLUM	143	26	19.26	2.51	1.65	3.81
VACCINATION SITE VESICLES	89	14	14.27	2.90	1.65	5.10
MYOCARDIAL ISCHAEMIA	142	26	18.92	2.49	1.64	3.79
C-REACTIVE PROTEIN INCREASED	79	12	13.11	3.01	1.64	5.52
ESCHERICHIA BACTERAEMIA	35	3	8.65	5.33	1.64	17.32
ACQUIRED DIAPHRAGMATIC EVENTRATION	50	6	10.14	3.80	1.63	8.87
SHOCK HAEMORRHAGIC	40	4	9.12	4.56	1.63	12.76
COLITIS ULCERATIVE	178	35	21.32	2.32	1.62	3.34
HYPERTHYROIDISM	174	34	21.05	2.34	1.62	3.37
HIP FRACTURE	110	19	15.78	2.64	1.62	4.30
GASTROINTESTINAL INFLAMMATION	78	12	12.74	2.97	1.62	5.45
AORTIC STENOSIS	100	17	14.60	2.69	1.61	4.49
CHRONIC RESPIRATORY FAILURE	73	11	12.16	3.03	1.61	5.71
ISCHAEMIC CARDIOMYOPATHY	73	11	12.16	3.03	1.61	5.71
COAGULOPATHY	181	36	21.27	2.30	1.60	3.28
COMMUNICATION DISORDER	164	32	19.85	2.34	1.60	3.42
TYPE IV HYPERSENSITIVITY REACTION	129	24	16.71	2.45	1.59	3.79
COLITIS MICROSCOPIC	63	9	11.02	3.20	1.59	6.42
SKIN TEXTURE ABNORMAL	63	9	11.02	3.20	1.59	6.42
INTRAVENTRICULAR HAEMORRHAGE	44	5	9.22	4.02	1.59	10.13
CIRCUMORAL SWELLING	39	4	8.71	4.45	1.59	12.45
AORTIC VALVE STENOSIS	34	3	8.23	5.17	1.59	16.84
LANGUAGE DISORDER	34	3	8.23	5.17	1.59	16.84
ORAL LICHEN PLANUS	34	3	8.23	5.17	1.59	16.84
PULSE ABNORMAL	334	75	31.55	2.03	1.58	2.61
BUNDLE BRANCH BLOCK RIGHT	227	48	24.01	2.16	1.58	2.95
PALATAL SWELLING	81	13	12.59	2.84	1.58	5.11
ATRIOVENTRICULAR BLOCK	136	26	16.90	2.39	1.57	3.63
LIP ERYTHEMA	136	26	16.90	2.39	1.57	3.63
LIP DISORDER	123	23	15.77	2.44	1.56	3.81
JAW DISORDER	110	20	14.65	2.51	1.56	4.04
MAST CELL ACTIVATION SYNDROME	62	9	10.64	3.14	1.56	6.33
BREAST INFLAMMATION	48	6	9.35	3.65	1.56	8.53
CHOLECYSTITIS ACUTE	48	6	9.35	3.65	1.56	8.53
PUPIL FIXED	273	61	25.95	2.04	1.55	2.70
SPINAL STENOSIS	88	15	12.71	2.68	1.55	4.63
INTRACRANIAL ANEURYSM	66	10	10.85	3.01	1.55	5.86
BREATH SOUNDS ABSENT	38	4	8.30	4.34	1.55	12.15
NEPHROSCLEROSIS	38	4	8.30	4.34	1.55	12.15
THIRST DECREASED	38	4	8.30	4.34	1.55	12.15
HAEMATEMESIS	253	56	24.49	2.06	1.54	2.75
CONJUNCTIVAL HAEMORRHAGE	125	24	15.37	2.38	1.54	3.68
FAECES SOFT	96	17	13.20	2.58	1.54	4.32
ELECTROCARDIOGRAM T WAVE INVERSION	83	14	12.11	2.71	1.54	4.77
SKIN ODOUR ABNORMAL	79	13	11.88	2.77	1.54	4.99
DECREASED NASOLABIAL FOLD	33	3	7.82	5.02	1.54	16.37
INCORRECT PRODUCT ADMINISTRATION DURATION	33	3	7.82	5.02	1.54	16.37
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	47	6	8.96	3.58	1.53	8.36
PULMONARY HYPERTENSION	215	47	21.26	2.09	1.52	2.86
NORMOCYTIC ANAEMIA	103	19	13.37	2.47	1.52	4.04
ANTIBIOTIC THERAPY	65	10	10.48	2.97	1.52	5.77
BLOOD URINE	42	5	8.42	3.83	1.52	9.69
FEEDING TUBE USER	42	5	8.42	3.83	1.52	9.69
PULMONARY HAEMORRHAGE	42	5	8.42	3.83	1.52	9.69
GINGIVAL SWELLING	224	50	21.23	2.04	1.51	2.78
SKIN WEEPING	131	26	15.26	2.30	1.51	3.50
PHYSICAL DECONDITIONING	115	22	14.17	2.39	1.51	3.76
CORONARY ARTERY BYPASS	90	16	12.26	2.57	1.51	4.37
BASAL GANGLIA INFARCTION	37	4	7.90	4.22	1.51	11.85
PERICARDIAL EXCISION	37	4	7.90	4.22	1.51	11.85
VACCINATION SITE JOINT PAIN	37	4	7.90	4.22	1.51	11.85
WRONG TECHNIQUE IN DEVICE USAGE PROCESS	37	4	7.90	4.22	1.51	11.85
USE OF ACCESSORY RESPIRATORY MUSCLES	138	28	15.50	2.25	1.50	3.38
PARKINSON'S DISEASE	106	20	13.30	2.42	1.50	3.90
CARDIOVASCULAR DISORDER	98	18	12.77	2.49	1.50	4.11
SLEEP TERROR	46	6	8.58	3.50	1.49	8.19
BLADDER SPASM	32	3	7.41	4.87	1.49	15.90
EPIDIDYMITIS	32	3	7.41	4.87	1.49	15.90
INNER EAR INFLAMMATION	32	3	7.41	4.87	1.49	15.90
PHANTOM LIMB SYNDROME	32	3	7.41	4.87	1.49	15.90
PANCREATITIS	216	49	19.75	2.01	1.48	2.74
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME	206	46	19.46	2.04	1.48	2.81
MIDDLE EAR EFFUSION	201	45	18.87	2.04	1.48	2.82
ACCIDENTAL UNDERDOSE	194	43	18.58	2.06	1.48	2.87
HYPERCAPNIA	167	36	16.84	2.12	1.48	3.04
PATIENT ISOLATION	50	7	8.76	3.26	1.48	7.19
EMBOLISM VENOUS	41	5	8.03	3.74	1.48	9.47
SUFFOCATION FEELING	41	5	8.03	3.74	1.48	9.47
PANCREATITIS ACUTE	139	29	14.83	2.19	1.47	3.26
AORTIC DILATATION	54	8	8.96	3.08	1.47	6.47
FACIAL SPASM	103	20	12.31	2.35	1.46	3.79
MASTITIS	99	19	12.04	2.38	1.46	3.89
NASAL PRURITUS	87	16	11.24	2.48	1.46	4.23
MENIERE'S DISEASE	83	15	10.98	2.53	1.46	4.38
BRAIN HERNIATION	45	6	8.20	3.42	1.46	8.02
ORAL BLOOD BLISTER	45	6	8.20	3.42	1.46	8.02
PATIENT UNCOOPERATIVE	36	4	7.50	4.11	1.46	11.54
EMPHYSEMA	172	38	16.52	2.07	1.45	2.94
DIARRHOEA HAEMORRHAGIC	157	34	15.65	2.11	1.45	3.05
FAILURE TO THRIVE	134	28	14.23	2.18	1.45	3.28
HEART SOUNDS ABNORMAL	134	28	14.23	2.18	1.45	3.28
BRONCHIAL WALL THICKENING	49	7	8.38	3.20	1.45	7.05
HANGOVER	86	16	10.90	2.45	1.44	4.18
INTESTINAL ISCHAEMIA	53	8	8.59	3.02	1.44	6.36
CORONAVIRUS INFECTION	40	5	7.64	3.65	1.44	9.25
MEDICAL DIET	40	5	7.64	3.65	1.44	9.25
VEIN DISCOLOURATION	40	5	7.64	3.65	1.44	9.25
BODY HEIGHT	31	3	7.00	4.72	1.44	15.43
RENAL ATROPHY	31	3	7.00	4.72	1.44	15.43
DYSCHROMATOPSIA	57	9	8.81	2.89	1.43	5.84
HYPERCOAGULATION	57	9	8.81	2.89	1.43	5.84
BLOOD POTASSIUM DECREASED	81	15	10.30	2.46	1.42	4.28
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	48	7	8.01	3.13	1.42	6.92
ENTERAL NUTRITION	35	4	7.11	3.99	1.42	11.24
RIGHT ATRIAL DILATATION	35	4	7.11	3.99	1.42	11.24
CAROTID ARTERY OCCLUSION	56	9	8.45	2.84	1.41	5.74
INJECTION SITE MUSCLE WEAKNESS	64	11	8.93	2.66	1.40	5.04
ANGIOPATHY	60	10	8.69	2.74	1.40	5.35
VENOUS THROMBOSIS LIMB	39	5	7.26	3.56	1.40	9.03
ABNORMAL FAECES	136	30	12.97	2.07	1.39	3.07
MELAENA	136	30	12.97	2.07	1.39	3.07
ACIDOSIS	91	18	10.46	2.31	1.39	3.83
ANTIALLERGIC THERAPY	47	7	7.64	3.06	1.39	6.78
INFARCTION	47	7	7.64	3.06	1.39	6.78
PUPILLARY LIGHT REFLEX TESTS ABNORMAL	47	7	7.64	3.06	1.39	6.78
ADULT FAILURE TO THRIVE	43	6	7.44	3.27	1.39	7.69
CONTRACEPTION	43	6	7.44	3.27	1.39	7.69
CUTANEOUS VASCULITIS	43	6	7.44	3.27	1.39	7.69
HIP SURGERY	30	3	6.59	4.56	1.39	14.96
VARICOSE VEIN	109	23	11.24	2.16	1.38	3.39
VULVOVAGINAL PAIN	109	23	11.24	2.16	1.38	3.39
LIVER DISORDER	98	20	10.70	2.24	1.38	3.62
STENOSIS	34	4	6.71	3.88	1.38	10.93
FRUSTRATION TOLERANCE DECREASED	134	30	12.38	2.04	1.37	3.03
BLADDER DISCOMFORT	38	5	6.88	3.47	1.37	8.81
UTERINE LEIOMYOMA	115	25	11.21	2.10	1.36	3.24
PERITONITIS	42	6	7.07	3.20	1.36	7.52
FEBRILE NEUTROPENIA	50	8	7.50	2.85	1.35	6.02
WALKING DISABILITY	46	7	7.28	3.00	1.35	6.64
TRIGGER FINGER	113	25	10.61	2.06	1.34	3.18
VACCINATION SITE IRRITATION	65	12	8.17	2.47	1.34	4.58
VITILIGO	65	12	8.17	2.47	1.34	4.58
ANTIPHOSPHOLIPID SYNDROME	29	3	6.19	4.41	1.34	14.49
PANCREATIC CARCINOMA	29	3	6.19	4.41	1.34	14.49
CONGESTIVE CARDIOMYOPATHY	76	15	8.66	2.31	1.33	4.02
THROMBOTIC THROMBOCYTOPENIC PURPURA	61	11	7.90	2.53	1.33	4.81
RED BLOOD CELL ABNORMALITY	37	5	6.50	3.38	1.33	8.59
HEMIPLEGIC MIGRAINE	33	4	6.32	3.77	1.33	10.63
LAZINESS	33	4	6.32	3.77	1.33	10.63
ATRIAL SEPTAL DEFECT	68	13	8.11	2.39	1.32	4.32
TONGUE ERUPTION	68	13	8.11	2.39	1.32	4.32
CRANIOTOMY	60	11	7.57	2.49	1.31	4.74
ATRIOVENTRICULAR BLOCK FIRST DEGREE	96	21	9.14	2.09	1.30	3.35
LICHEN PLANUS	96	21	9.14	2.09	1.30	3.35
HYDRONEPHROSIS	85	18	8.57	2.16	1.30	3.58
FEMUR FRACTURE	56	10	7.30	2.56	1.30	5.01
DYSPNOEA PAROXYSMAL NOCTURNAL	48	8	6.80	2.74	1.30	5.79
HEART INJURY	28	3	5.79	4.26	1.30	14.01
OVARIAN CYST RUPTURED	28	3	5.79	4.26	1.30	14.01
LAPAROSCOPIC SURGERY	102	23	9.14	2.02	1.29	3.18
ALOPECIA AREATA	92	20	8.85	2.10	1.29	3.41
CARDIAC VALVE DISEASE	40	6	6.33	3.04	1.29	7.18
GALLBLADDER ENLARGEMENT	36	5	6.12	3.29	1.29	8.38
REDUCED FACIAL EXPRESSION	36	5	6.12	3.29	1.29	8.38
ATTENTION DEFICIT HYPERACTIVITY DISORDER	32	4	5.94	3.65	1.29	10.33
EYE COLOUR CHANGE	32	4	5.94	3.65	1.29	10.33
UPPER GASTROINTESTINAL HAEMORRHAGE	66	13	7.46	2.32	1.28	4.20
CHRONIC LYMPHOCYTIC LEUKAEMIA	55	10	6.97	2.51	1.28	4.92
ENDOCARDITIS	55	10	6.97	2.51	1.28	4.92
MANIA	73	15	7.71	2.22	1.27	3.87
COLITIS ISCHAEMIC	62	12	7.18	2.36	1.27	4.38
EFFUSION	62	12	7.18	2.36	1.27	4.38
FEELING OF DESPAIR	62	12	7.18	2.36	1.27	4.38
PNEUMOMEDIASTINUM	43	7	6.20	2.80	1.26	6.23
EPISCLERITIS	39	6	5.97	2.97	1.26	7.01
RESPIRATORY ACIDOSIS	61	12	6.86	2.32	1.25	4.31
STAPHYLOCOCCAL BACTERAEMIA	61	12	6.86	2.32	1.25	4.31
OESOPHAGEAL SPASM	50	9	6.37	2.54	1.25	5.16
INTRACRANIAL MASS	35	5	5.75	3.20	1.25	8.16
ANAL HAEMORRHAGE	31	4	5.56	3.54	1.25	10.02
APTYALISM	31	4	5.56	3.54	1.25	10.02
PULMONARY ARTERIAL HYPERTENSION	27	3	5.40	4.11	1.25	13.54
TONGUE DRY	85	19	7.66	2.04	1.24	3.36
BLOOD GLUCOSE FLUCTUATION	57	11	6.58	2.37	1.24	4.51
LIVER INJURY	57	11	6.58	2.37	1.24	4.51
PERIPHERAL VENOUS DISEASE	74	16	7.08	2.11	1.23	3.62
SICK RELATIVE	53	10	6.30	2.42	1.23	4.76
YAWNING	70	15	6.79	2.13	1.22	3.72
CARDIAC OPERATION	49	9	6.03	2.49	1.22	5.06
COLECTOMY	49	9	6.03	2.49	1.22	5.06
ISCHAEMIC HEPATITIS	49	9	6.03	2.49	1.22	5.06
GENITAL ULCERATION	38	6	5.61	2.89	1.22	6.84
ENTERITIS	45	8	5.77	2.57	1.21	5.45
CAPILLARY FRAGILITY	34	5	5.39	3.10	1.21	7.94
CARDIOPULMONARY FAILURE	34	5	5.39	3.10	1.21	7.94
INTESTINAL PERFORATION	34	5	5.39	3.10	1.21	7.94
B-CELL LYMPHOMA	30	4	5.18	3.42	1.21	9.72
HIDRADENITIS	30	4	5.18	3.42	1.21	9.72
LEG AMPUTATION	30	4	5.18	3.42	1.21	9.72
MUCOSAL HYPERTROPHY	30	4	5.18	3.42	1.21	9.72
NEUTROPHILIA	30	4	5.18	3.42	1.21	9.72
CLOSTRIDIUM DIFFICILE INFECTION	62	13	6.20	2.18	1.20	3.96
BRAIN STEM INFARCTION	41	7	5.51	2.67	1.20	5.96
ELECTROCARDIOGRAM AMBULATORY	41	7	5.51	2.67	1.20	5.96
GENITAL PAIN	41	7	5.51	2.67	1.20	5.96
ABDOMINAL REBOUND TENDERNESS	26	3	5.01	3.96	1.20	13.07
BRAIN STEM STROKE	26	3	5.01	3.96	1.20	13.07
REPETITIVE SPEECH	26	3	5.01	3.96	1.20	13.07
BRAIN DEATH	48	9	5.70	2.43	1.19	4.96
SKIN WRINKLING	48	9	5.70	2.43	1.19	4.96
GINGIVAL DISCOMFORT	51	10	5.66	2.33	1.18	4.59
VITAMIN D DECREASED	44	8	5.43	2.51	1.18	5.33
ENDOMETRIOSIS	40	7	5.17	2.61	1.17	5.82
HAEMOLYSIS	40	7	5.17	2.61	1.17	5.82
OESOPHAGEAL DISORDER	40	7	5.17	2.61	1.17	5.82
FACIAL BONES FRACTURE	67	15	5.90	2.04	1.16	3.57
TONGUE MOVEMENT DISTURBANCE	50	10	5.34	2.28	1.16	4.50
ACNE CYSTIC	29	4	4.81	3.31	1.16	9.41
OESOPHAGEAL PAIN	53	11	5.32	2.20	1.15	4.21
INTERNATIONAL NORMALISED RATIO INCREASED	43	8	5.10	2.45	1.15	5.22
POST VIRAL FATIGUE SYNDROME	36	6	4.91	2.74	1.15	6.50
COR PULMONALE	25	3	4.62	3.80	1.15	12.60
INSULIN-REQUIRING TYPE 2 DIABETES MELLITUS	25	3	4.62	3.80	1.15	12.60
LOGORRHOEA	25	3	4.62	3.80	1.15	12.60
RENAL TRANSPLANT	25	3	4.62	3.80	1.15	12.60
RESPIRATORY TRACT IRRITATION	59	13	5.30	2.07	1.14	3.78
URETERAL STENT INSERTION	32	5	4.67	2.92	1.14	7.50
PLASMA CELL MYELOMA	49	10	5.03	2.24	1.13	4.42
NASAL INJURY	58	13	5.01	2.04	1.12	3.72
FIBROSIS	28	4	4.44	3.20	1.12	9.11
TACHYARRHYTHMIA	48	10	4.72	2.19	1.11	4.33
VENA CAVA FILTER INSERTION	48	10	4.72	2.19	1.11	4.33
GANGRENE	31	5	4.32	2.83	1.10	7.28
VENTRICULAR ARRHYTHMIA	31	5	4.32	2.83	1.10	7.28
ADENOCARCINOMA	24	3	4.24	3.65	1.10	12.13
LOSS OF BLADDER SENSATION	24	3	4.24	3.65	1.10	12.13
LOWER GASTROINTESTINAL HAEMORRHAGE	24	3	4.24	3.65	1.10	12.13
METASTASES TO LIVER	24	3	4.24	3.65	1.10	12.13
COMPLICATION ASSOCIATED WITH DEVICE	44	9	4.43	2.23	1.09	4.57
SUBMAXILLARY GLAND ENLARGEMENT	34	6	4.23	2.59	1.09	6.16
CAPILLARY NAIL REFILL TEST ABNORMAL	47	10	4.42	2.15	1.08	4.25
SINUS ARREST	27	4	4.08	3.08	1.08	8.81
BLOOD GLUCOSE NORMAL	49	11	4.13	2.03	1.06	3.91
LIP HAEMORRHAGE	49	11	4.13	2.03	1.06	3.91
NASAL DISORDER	43	9	4.13	2.18	1.06	4.47
NEPHROTIC SYNDROME	43	9	4.13	2.18	1.06	4.47
ATELECTASIS	725	165	67.25	2.01	1.69	2.37
MENTAL IMPAIRMENT	689	156	64.60	2.02	1.69	2.40
RESPIRATION ABNORMAL	439	99	41.29	2.02	1.63	2.52
EAR INFECTION	375	85	34.79	2.01	1.59	2.55
CARDIAC PACEMAKER INSERTION	238	54	21.81	2.01	1.50	2.70
MOOD SWINGS	186	42	17.10	2.02	1.45	2.83
HAEMODIALYSIS	142	32	12.97	2.03	1.38	2.97
BUNDLE BRANCH BLOCK LEFT	128	29	11.50	2.01	1.35	3.01
SKIN DISCOMFORT	97	22	8.55	2.01	1.27	3.20
SPECIALIST CONSULTATION	79	18	6.79	2.00	1.20	3.34
NORMAL LABOUR	25	3	4.62	3.80	1.15	12.60
ANTINUCLEAR ANTIBODY POSITIVE	35	6	4.57	2.66	1.12	6.33
ABDOMINAL HERNIA	34	6	4.23	2.59	1.09	6.16
DISEASE RECURRENCE	225	2	96.49	51.35	12.76	206.60
CEREBRAL THROMBOSIS	186	1	81.06	84.90	11.90	605.91
COVID-19 IMMUNISATION	191	2	80.98	43.59	10.82	175.57
CEREBRAL VENOUS SINUS THROMBOSIS	150	1	64.64	68.47	9.58	489.26
INTENTIONAL PRODUCT USE ISSUE	141	1	60.53	64.36	9.00	460.09
SARS-COV-2 TEST NEGATIVE	107	1	45.03	48.84	6.82	349.92
HYPERPYREXIA	100	1	41.84	45.65	6.37	327.23
INTENTIONAL DOSE OMISSION	92	1	38.20	42.00	5.85	301.31
RIGHT VENTRICULAR DYSFUNCTION	88	1	36.38	40.17	5.60	288.35
INTRACARDIAC THROMBUS	94	2	36.85	21.45	5.29	87.05
CEREBRAL ARTERY OCCLUSION	93	2	36.39	21.23	5.23	86.14
ABNORMAL UTERINE BLEEDING	82	1	33.65	37.43	5.21	268.91
LYMPHOPENIA	89	2	34.58	20.31	5.00	82.49
CEREBELLAR STROKE	75	1	30.46	34.24	4.76	246.22
SARS-COV-2 ANTIBODY TEST NEGATIVE	71	1	28.64	32.41	4.50	233.26
CEREBRAL MASS EFFECT	70	1	28.19	31.95	4.44	230.02
RIGHT VENTRICULAR DILATATION	67	1	26.83	30.58	4.25	220.30
PERIPHERAL ARTERY THROMBOSIS	75	2	28.25	17.12	4.20	69.71
VACCINATION SITE PARAESTHESIA	73	2	27.34	16.66	4.09	67.89
MYOCARDIAL STRAIN	64	1	25.46	29.21	4.05	210.58
PORTAL VEIN THROMBOSIS	71	2	26.44	16.20	3.97	66.06
INTERNAL HAEMORRHAGE	67	2	24.64	15.29	3.75	62.41
IMPLANTABLE CARDIAC MONITOR INSERTION	58	1	22.74	26.48	3.67	191.14
CHILLBLAINS	65	2	23.74	14.84	3.63	60.59
PRE-EXISTING CONDITION IMPROVED	65	2	23.74	14.84	3.63	60.59
BODY HEIGHT DECREASED	57	1	22.29	26.02	3.60	187.90
TRANSVERSE SINUS THROMBOSIS	55	1	21.38	25.11	3.47	181.42
HAEMOFILTRATION	52	1	20.02	23.74	3.28	171.70
CRITICAL ILLNESS	58	2	20.59	13.24	3.23	54.20
MESENTERIC VEIN THROMBOSIS	51	1	19.57	23.28	3.22	168.46
CORONARY ARTERY DISSECTION	50	1	19.12	22.82	3.15	165.22
JUGULAR VEIN THROMBOSIS	49	1	18.66	22.37	3.09	161.98
NIH STROKE SCALE	48	1	18.21	21.91	3.02	158.74
NIH STROKE SCALE ABNORMAL	47	1	17.76	21.45	2.96	155.50
NEUROLOGIC NEGLECT SYNDROME	46	1	17.31	21.00	2.90	152.26
COOLING THERAPY	52	2	17.91	11.87	2.89	48.72
LEFT VENTRICULAR DILATATION	45	1	16.86	20.54	2.83	149.02
PLATELET COUNT INCREASED	45	1	16.86	20.54	2.83	149.02
THROMBOEMBOLECTOMY	45	1	16.86	20.54	2.83	149.02
DEPERSONALISATION/DEREALISATION DISORDER	44	1	16.40	20.08	2.77	145.78
PREMENSTRUAL PAIN	44	1	16.40	20.08	2.77	145.78
PRODUCT RECONSTITUTION QUALITY ISSUE	44	1	16.40	20.08	2.77	145.78
COR PULMONALE ACUTE	42	1	15.50	19.17	2.64	139.30
HEPATIC MASS	42	1	15.50	19.17	2.64	139.30
TOTAL LUNG CAPACITY DECREASED	41	1	15.05	18.72	2.57	136.06
SENSATION OF BLOOD FLOW	46	2	15.23	10.50	2.55	43.25
PERIPHERAL ARTERY OCCLUSION	40	1	14.60	18.26	2.51	132.81
AORTIC DISSECTION	44	2	14.35	10.04	2.43	41.42
CARDIAC FAILURE CHRONIC	44	2	14.35	10.04	2.43	41.42
MYOCARDIAL FIBROSIS	43	2	13.90	9.81	2.38	40.51
FREEZING PHENOMENON	38	1	13.70	17.35	2.38	126.33
LUNG ASSIST DEVICE THERAPY	42	2	13.46	9.59	2.32	39.60
ACUTE CARDIAC EVENT	37	1	13.25	16.89	2.32	123.10
SENSITISATION	37	1	13.25	16.89	2.32	123.10
BRAIN OPERATION	41	2	13.02	9.36	2.26	38.69
SUBDURAL HAEMORRHAGE	41	2	13.02	9.36	2.26	38.69
CARDIOVASCULAR SYMPTOM	36	1	12.80	16.43	2.25	119.86
FEELING OF RELAXATION	36	1	12.80	16.43	2.25	119.86
GLYCOSYLATED HAEMOGLOBIN INCREASED	40	2	12.58	9.13	2.21	37.77
NIH STROKE SCALE SCORE INCREASED	40	2	12.58	9.13	2.21	37.77
RED BLOOD CELL COUNT DECREASED	40	2	12.58	9.13	2.21	37.77
PRODUCT ADMINISTRATION INTERRUPTED	34	1	11.91	15.52	2.12	113.38
ARTERIAL CATHETERISATION	38	2	11.70	8.67	2.09	35.95
VESTIBULAR MIGRAINE	38	2	11.70	8.67	2.09	35.95
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	33	1	11.46	15.06	2.06	110.14
LACUNAR STROKE	33	1	11.46	15.06	2.06	110.14
PLEURAL THICKENING	33	1	11.46	15.06	2.06	110.14
VITAL FUNCTIONS ABNORMAL	33	1	11.46	15.06	2.06	110.14
PARANASAL SINUS INFLAMMATION	37	2	11.27	8.44	2.04	35.04
CEREBRAL ARTERY STENOSIS	36	2	10.83	8.22	1.98	34.12
CHILD MALTREATMENT SYNDROME	31	1	10.56	14.15	1.93	103.66
LACK OF SPONTANEOUS SPEECH	31	1	10.56	14.15	1.93	103.66
MITRAL VALVE CALCIFICATION	31	1	10.56	14.15	1.93	103.66
AORTIC VALVE REPLACEMENT	35	2	10.39	7.99	1.92	33.21
RESPIRATORY SYNCYTIAL VIRUS INFECTION	35	2	10.39	7.99	1.92	33.21
ARTERIAL THROMBOSIS	30	1	10.12	13.69	1.87	100.42
RETINAL MIGRAINE	34	2	9.96	7.76	1.86	32.30
OVERSENSING	33	2	9.52	7.53	1.81	31.39
COLON CANCER	29	1	9.67	13.24	1.80	97.18
CYTOKINE STORM	29	1	9.67	13.24	1.80	97.18
EYELID SENSORY DISORDER	29	1	9.67	13.24	1.80	97.18
INTRA-ABDOMINAL FLUID COLLECTION	29	1	9.67	13.24	1.80	97.18
METASTASES TO BONE	29	1	9.67	13.24	1.80	97.18
ENDOMETRIAL THICKENING	32	2	9.09	7.30	1.75	30.48
INJECTION	32	2	9.09	7.30	1.75	30.48
VACCINATION SITE SCAR	32	2	9.09	7.30	1.75	30.48
CEREBRAL ARTERY EMBOLISM	28	1	9.23	12.78	1.74	93.94
DIURETIC THERAPY	28	1	9.23	12.78	1.74	93.94
URINARY TRACT DISCOMFORT	28	1	9.23	12.78	1.74	93.94
IDIOPATHIC INTRACRANIAL HYPERTENSION	31	2	8.66	7.08	1.69	29.56
THYROID PAIN	31	2	8.66	7.08	1.69	29.56
DAYDREAMING	27	1	8.79	12.32	1.67	90.70
PRODUCT DOSE OMISSION IN ERROR	27	1	8.79	12.32	1.67	90.70
BEHAVIOUR DISORDER	30	2	8.23	6.85	1.64	28.65
PRODUCT AVAILABILITY ISSUE	30	2	8.23	6.85	1.64	28.65
HAEMORRHAGIC TRANSFORMATION STROKE	26	1	8.34	11.87	1.61	87.46
INJECTION RELATED REACTION	26	1	8.34	11.87	1.61	87.46
OVULATION DISORDER	26	1	8.34	11.87	1.61	87.46
PARAESTHESIA EAR	26	1	8.34	11.87	1.61	87.46
RIGHT ATRIAL ENLARGEMENT	26	1	8.34	11.87	1.61	87.46
COLD-STIMULUS HEADACHE	29	2	7.81	6.62	1.58	27.74
HYPERVIGILANCE	29	2	7.81	6.62	1.58	27.74
SUBCLAVIAN VEIN THROMBOSIS	29	2	7.81	6.62	1.58	27.74
VASCULAR DEMENTIA	25	1	7.90	11.41	1.55	84.22
DYSHIDROTIC ECZEMA	28	2	7.38	6.39	1.52	26.83
LEFT VENTRICULAR ENLARGEMENT	24	1	7.46	10.96	1.48	80.98
MENSTRUATION NORMAL	24	1	7.46	10.96	1.48	80.98
SEDATIVE THERAPY	24	1	7.46	10.96	1.48	80.98
MULTIMORBIDITY	27	2	6.96	6.16	1.47	25.91
PULMONARY VASCULAR DISORDER	27	2	6.96	6.16	1.47	25.91
VASOGENIC CEREBRAL OEDEMA	27	2	6.96	6.16	1.47	25.91
BASAL GANGLIA HAEMORRHAGE	23	1	7.02	10.50	1.42	77.74
BREAST DISORDER FEMALE	23	1	7.02	10.50	1.42	77.74
EAR INFLAMMATION	23	1	7.02	10.50	1.42	77.74
INFERIOR VENA CAVA DILATATION	23	1	7.02	10.50	1.42	77.74
VEIN RUPTURE	23	1	7.02	10.50	1.42	77.74
ANTIINFLAMMATORY THERAPY	26	2	6.54	5.93	1.41	25.00
AORTIC THROMBOSIS	26	2	6.54	5.93	1.41	25.00
THORACIC CAVITY DRAINAGE	26	2	6.54	5.93	1.41	25.00
FOOD CRAVING	25	2	6.12	5.71	1.35	24.09
HAND DERMATITIS	25	2	6.12	5.71	1.35	24.09
PRODUCT DISPENSING ISSUE	22	1	6.58	10.04	1.35	74.50
ANEMBRYONIC GESTATION	24	2	5.70	5.48	1.29	23.18
PANCREATIC CYST	24	2	5.70	5.48	1.29	23.18
PULMONARY CALCIFICATION	24	2	5.70	5.48	1.29	23.18
DENTAL PARAESTHESIA	21	1	6.15	9.59	1.29	71.26
ORBITAL SWELLING	21	1	6.15	9.59	1.29	71.26
PLATELET DISORDER	21	1	6.15	9.59	1.29	71.26
SUPERFICIAL VEIN PROMINENCE	21	1	6.15	9.59	1.29	71.26
ORGANISING PNEUMONIA	23	2	5.29	5.25	1.24	22.26
PATHOGEN RESISTANCE	23	2	5.29	5.25	1.24	22.26
PNEUMOPERITONEUM	23	2	5.29	5.25	1.24	22.26
THROMBOSIS PROPHYLAXIS	23	2	5.29	5.25	1.24	22.26
BLUE TOE SYNDROME	20	1	5.71	9.13	1.23	68.02
CHEYNE-STOKES RESPIRATION	20	1	5.71	9.13	1.23	68.02
FEMORAL NECK FRACTURE	20	1	5.71	9.13	1.23	68.02
LARGE INTESTINE PERFORATION	20	1	5.71	9.13	1.23	68.02
LOSS OF LIBIDO	20	1	5.71	9.13	1.23	68.02
OXYGEN CONSUMPTION DECREASED	20	1	5.71	9.13	1.23	68.02
PULMONARY ARTERY DILATATION	20	1	5.71	9.13	1.23	68.02
SPLENIC VEIN THROMBOSIS	20	1	5.71	9.13	1.23	68.02
AORTIC DISORDER	22	2	4.88	5.02	1.18	21.35
CHOLECYSTITIS INFECTIVE	22	2	4.88	5.02	1.18	21.35
CORNEAL LIGHT REFLEX TEST ABNORMAL	22	2	4.88	5.02	1.18	21.35
VENTRICULAR DRAINAGE	22	2	4.88	5.02	1.18	21.35
FASTING	19	1	5.28	8.67	1.16	64.79
METASTASES TO LYMPH NODES	19	1	5.28	8.67	1.16	64.79
MONOCLONAL ANTIBODY UNCONJUGATED THERAPY	19	1	5.28	8.67	1.16	64.79
NEUTROPHIL COUNT INCREASED	19	1	5.28	8.67	1.16	64.79
METASTASES TO CENTRAL NERVOUS SYSTEM	21	2	4.48	4.79	1.12	20.44
VERTEBRAL ARTERY OCCLUSION	21	2	4.48	4.79	1.12	20.44
ARTERIAL STENT INSERTION	18	1	4.85	8.22	1.10	61.55
CEREBRAL HAEMATOMA	18	1	4.85	8.22	1.10	61.55
DECEREBRATE POSTURE	18	1	4.85	8.22	1.10	61.55
GASTRIC HAEMORRHAGE	18	1	4.85	8.22	1.10	61.55
HAEMOPERITONEUM	18	1	4.85	8.22	1.10	61.55
OXYGEN CONSUMPTION INCREASED	18	1	4.85	8.22	1.10	61.55
VACCINATION SITE COLDNESS	18	1	4.85	8.22	1.10	61.55
VENTRICULAR ASSIST DEVICE INSERTION	18	1	4.85	8.22	1.10	61.55
ANOVULATORY CYCLE	20	2	4.08	4.56	1.07	19.53
BLOOD THYROID STIMULATING HORMONE DECREASED	20	2	4.08	4.56	1.07	19.53
CHOLANGITIS	20	2	4.08	4.56	1.07	19.53
MITRAL VALVE STENOSIS	20	2	4.08	4.56	1.07	19.53
NEUTROPHIL COUNT DECREASED	20	2	4.08	4.56	1.07	19.53
SACRAL PAIN	20	2	4.08	4.56	1.07	19.53
THUNDERCLAP HEADACHE	20	2	4.08	4.56	1.07	19.53
ABDOMINAL WALL HAEMATOMA	17	1	4.43	7.76	1.03	58.31
EMBOLIC CEREBRAL INFARCTION	17	1	4.43	7.76	1.03	58.31
ENDOMETRIAL ABLATION	17	1	4.43	7.76	1.03	58.31
EPSTEIN-BARR VIRUS INFECTION REACTIVATION	17	1	4.43	7.76	1.03	58.31
RED BLOOD CELL COUNT INCREASED	17	1	4.43	7.76	1.03	58.31
RENAL STONE REMOVAL	17	1	4.43	7.76	1.03	58.31
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION	17	1	4.43	7.76	1.03	58.31
TERMINAL INSOMNIA	17	1	4.43	7.76	1.03	58.31
BREAST CANCER METASTATIC	16	1	4.01	7.30	0.97	55.07
CARDIAC ANEURYSM	16	1	4.01	7.30	0.97	55.07
GALACTOSTASIS	16	1	4.01	7.30	0.97	55.07
HAEMORRHOIDS THROMBOSED	16	1	4.01	7.30	0.97	55.07
INFECTIOUS PLEURAL EFFUSION	16	1	4.01	7.30	0.97	55.07
INTRUSIVE THOUGHTS	16	1	4.01	7.30	0.97	55.07
POSITIVE END-EXPIRATORY PRESSURE	16	1	4.01	7.30	0.97	55.07
SINONASAL OBSTRUCTION	16	1	4.01	7.30	0.97	55.07
UTERINE POLYP	16	1	4.01	7.30	0.97	55.07
VASCULAR PSEUDOANEURYSM	16	1	4.01	7.30	0.97	55.07
VOLVULUS	16	1	4.01	7.30	0.97	55.07
BLOOD LACTIC ACID INCREASED	20	2	4.08	4.56	1.07	19.53
VERTEBRAL ARTERY STENOSIS	20	2	4.08	4.56	1.07	19.53
CAPILLARY DISORDER	16	1	4.01	7.30	0.97	55.07
DEFAECATION DISORDER	16	1	4.01	7.30	0.97	55.07
DISTRIBUTIVE SHOCK	16	1	4.01	7.30	0.97	55.07
FOLLICULAR LYMPHOMA	16	1	4.01	7.30	0.97	55.07
THERAPEUTIC PRODUCT EFFECT DECREASED	16	1	4.01	7.30	0.97	55.07
TOE AMPUTATION	16	1	4.01	7.30	0.97	55.07
URINARY BLADDER HAEMORRHAGE	16	1	4.01	7.30	0.97	55.07
WRONG PATIENT	47	1	17.76	21.45	2.96	155.50
PAIN ASSESSMENT	12	1	2.37	5.48	0.71	42.13
PROCTITIS ULCERATIVE	6	1	0.32	2.74	0.33	22.75

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• SERIOUS AGES 5 YEARS-11 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• SERIOUS AGES 5 YEARS-11 YEARS excludes missing ages

MedDRA Codes ALL Reports (SERIOUS AGES 5 YEARS-11 YEARS)	12/14/2020-03/18/2022 COVID19 mRNA N=228	01/01/2009-03/18/2022 NON-COVID19 N=1885	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
APPENDICITIS	12	3	68.11	33.07	9.40	116.31
MYOCARDITIS	10	4	47.68	20.67	6.54	65.36
CONJUNCTIVITIS	16	10	65.19	13.23	6.08	28.80
KAWASAKI'S DISEASE	7	3	30.67	19.29	5.02	74.08
APPENDICECTOMY	8	8	21.81	8.27	3.13	21.82
CHEST PAIN	25	48	40.73	4.31	2.71	6.84
SHOCK	6	6	15.40	8.27	2.69	25.42
HYPOTENSION	14	25	23.43	4.63	2.44	8.78
CONJUNCTIVAL HYPERAEMIA	6	8	11.89	6.20	2.17	17.71
ABDOMINAL PAIN LOWER	4	4	9.06	8.27	2.08	32.83
SEIZURE	22	60	21.10	3.03	1.90	4.84
ERYTHEMA MULTIFORME	3	3	5.96	8.27	1.68	40.72
GASTROINTESTINAL DISORDER	3	3	5.96	8.27	1.68	40.72
PANIC ATTACK	3	3	5.96	8.27	1.68	40.72
CONDITION AGGRAVATED	21	67	14.92	2.59	1.62	4.15
INFLAMMATION	7	15	8.12	3.86	1.59	9.36
NEPHROTIC SYNDROME	3	4	4.53	6.20	1.40	27.53
PAINFUL RESPIRATION	3	4	4.53	6.20	1.40	27.53
ACUTE RESPIRATORY FAILURE	4	7	5.08	4.72	1.39	16.01
HEART RATE INCREASED	7	20	5.01	2.89	1.24	6.77
HYPOXIA	7	22	4.13	2.63	1.14	6.09
CHAPPED LIPS	4	5	7.41	6.61	1.79	24.45
RASH	32	128	14.24	2.07	1.44	2.97
HYPONATRAEMIA	4	8	4.23	4.13	1.25	13.62
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	33	1	258.13	272.83	37.49	1985.31
COVID-19	29	1	224.19	239.76	32.82	1751.73
LEFT VENTRICULAR DYSFUNCTION	8	1	49.41	66.14	8.31	526.41
ILLNESS	5	1	25.77	41.34	4.85	352.27
PERICARDIAL EFFUSION	5	1	25.77	41.34	4.85	352.27
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	4	1	18.25	33.07	3.71	294.60
PERICARDITIS	4	1	18.25	33.07	3.71	294.60
TRICUSPID VALVE INCOMPETENCE	3	1	11.13	24.80	2.59	237.45
HEPATOMEGALY	3	2	8.00	12.40	2.08	73.83
PLEURAL EFFUSION	3	2	8.00	12.40	2.08	73.83
VENTRICULAR EXTRASYSTOLES	3	2	8.00	12.40	2.08	73.83

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• SERIOUS AGES 12 YEARS-17 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• SERIOUS AGES 12 YEARS-17 YEARS excludes missing ages

MedDRA Codes ALL Reports (SERIOUS 12 Yrs-17 Yrs)	12/14/2020-03/18/2022 COVID19 mRNA N=1772	01/01/2009-03/18/2022 NON-COVID19 N=2387	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
MYOCARDITIS	636	12	965.66	71.39	40.46	125.97
RESPIRATORY RATE INCREASED	143	6	177.73	32.11	14.22	72.49
PERICARDITIS	143	9	168.76	21.40	10.94	41.86
BLOOD PRESSURE INCREASED	122	14	125.56	11.74	6.78	20.34
PAINFUL RESPIRATION	84	9	86.59	12.57	6.34	24.93
ANTICOAGULANT THERAPY	51	4	55.20	17.18	6.22	47.43
CHEST PAIN	873	168	964.21	7.00	6.01	8.16
PERICARDIAL EFFUSION	60	7	59.44	11.55	5.29	25.20
RESPIRATORY RATE DECREASED	38	3	40.42	17.06	5.28	55.19
HEART RATE DECREASED	57	7	55.45	10.97	5.02	23.99
PLEURITIC PAIN	33	3	33.75	14.82	4.55	48.24
CHEST DISCOMFORT	250	61	194.53	5.52	4.20	7.25
HEART RATE INCREASED	177	52	117.74	4.59	3.39	6.21
SINUS ARRHYTHMIA	24	3	21.94	10.78	3.25	35.73
APPENDICITIS	51	12	36.89	5.73	3.06	10.70
BLOOD PRESSURE DECREASED	76	21	50.41	4.88	3.02	7.87
BODY TEMPERATURE INCREASED	77	24	46.48	4.32	2.74	6.81
PULMONARY EMBOLISM	25	5	18.85	6.74	2.58	17.56
TACHYPNOEA	60	20	33.67	4.04	2.45	6.68
INTENSIVE CARE	339	157	151.40	2.91	2.43	3.48
ACUTE KIDNEY INJURY	29	8	18.09	4.88	2.24	10.66
SINUS TACHYCARDIA	39	14	19.80	3.75	2.04	6.89
OXYGEN SATURATION DECREASED	48	19	22.29	3.40	2.01	5.77
MUSCULOSKELETAL CHEST PAIN	37	14	17.71	3.56	1.93	6.56
DECREASED ACTIVITY	45	19	19.27	3.19	1.87	5.43
LYMPHOPENIA	14	3	9.46	6.29	1.81	21.84
DYSPNOEA	384	250	97.82	2.07	1.79	2.40
SINUS BRADYCARDIA	19	6	10.14	4.27	1.71	10.66
TACHYCARDIA	203	131	48.24	2.09	1.69	2.58
BREATH SOUNDS ABNORMAL	32	14	12.73	3.08	1.65	5.75
PALPITATIONS	122	76	29.91	2.16	1.63	2.86
VACCINATION COMPLICATION	133	85	31.07	2.11	1.62	2.75
APPENDICECTOMY	42	22	13.14	2.57	1.54	4.29
LIMB DISCOMFORT	31	15	10.68	2.78	1.51	5.14
ACUTE RESPIRATORY FAILURE	21	9	8.18	3.14	1.44	6.85
HEAVY MENSTRUAL BLEEDING	13	4	6.68	4.38	1.43	13.40
ELECTROCARDIOGRAM AMBULATORY	11	3	6.03	4.94	1.38	17.68
OROPHARYNGEAL DISCOMFORT	11	3	6.03	4.94	1.38	17.68
ABDOMINAL PAIN LOWER	35	20	9.23	2.36	1.37	4.07
STEROID THERAPY	17	7	6.75	3.27	1.36	7.87
THROMBOSIS	15	6	6.03	3.37	1.31	8.66
TRANSAMINASES INCREASED	15	6	6.03	3.37	1.31	8.66
PLEURAL EFFUSION	24	13	6.67	2.49	1.27	4.87
DYSPNOEA EXERTIONAL	30	19	6.28	2.13	1.20	3.77
PAIN IN JAW	24	14	5.80	2.31	1.20	4.45
INFLAMMATION	30	20	5.56	2.02	1.15	3.55
CARDIAC ARREST	22	13	5.11	2.28	1.15	4.51
IMMUNE THROMBOCYTOPENIA	12	5	4.38	3.23	1.14	9.16
HYPOXIA	27	18	4.93	2.02	1.12	3.66
CONJUNCTIVITIS	19	11	4.49	2.33	1.11	4.88
CARDIOMEGALY	13	6	4.20	2.92	1.11	7.66
ELECTROCARDIOGRAM QT PROLONGED	10	3	4.95	4.49	1.24	16.29
BRADYCARDIA	39	26	7.46	2.02	1.23	3.31
TROPONIN INCREASED	121	1	162.13	162.99	22.80	1165.38
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	111	1	147.90	149.52	20.90	1069.85
COVID-19	94	2	120.63	63.31	15.62	256.54
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	52	1	65.36	70.05	9.69	506.20
VENTRICULAR TACHYCARDIA	39	2	44.56	26.27	6.35	108.64
TROPONIN I INCREASED	33	1	39.35	44.45	6.09	324.71
MITRAL VALVE INCOMPETENCE	31	1	36.63	41.76	5.71	305.60
VENTRICULAR EXTRASYSTOLES	28	1	32.57	37.72	5.14	276.95
EPINEPHRINE	22	1	24.48	29.64	4.00	219.65
TRICUSPID VALVE INCOMPETENCE	22	1	24.48	29.64	4.00	219.65
BLOOD PRESSURE DIASTOLIC INCREASED	18	1	19.12	24.25	3.24	181.46
ILLNESS	16	1	16.47	21.55	2.86	162.37
ELECTROCARDIOGRAM T WAVE INVERSION	14	2	11.46	9.43	2.15	41.44
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	14	2	11.46	9.43	2.15	41.44
HEART SOUNDS ABNORMAL	13	2	10.21	8.76	1.98	38.75
EXPOSURE TO SARS-COV-2	10	1	8.64	13.47	1.73	105.13
SEDATION	10	1	8.64	13.47	1.73	105.13
APPENDICITIS PERFORATED	9	1	7.37	12.12	1.54	95.60
PHARYNGEAL SWELLING	9	1	7.37	12.12	1.54	95.60
BLOOD PRESSURE SYSTOLIC DECREASED	10	2	6.58	6.74	1.48	30.70
ISCHAEMIC STROKE	10	2	6.58	6.74	1.48	30.70
C-REACTIVE PROTEIN INCREASED	8	1	6.12	10.78	1.35	86.08
PULMONARY VALVE INCOMPETENCE	8	1	6.12	10.78	1.35	86.08
BUNDLE BRANCH BLOCK RIGHT	7	1	4.89	9.43	1.16	76.57
ANGINA PECTORIS	8	2	4.30	5.39	1.15	25.34
LYMPH NODE PAIN	8	2	4.30	5.39	1.15	25.34

• PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
• For Current Week and Past Week Comparison
• Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
• Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
• SERIOUS AGES 18+ YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
• Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
• N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
• MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
• SERIOUS AGES 18+ YEARS YEARS excludes missing ages

MedDRA Codes ALL Reports (18+)	12/14/2020-03/18/2022 COVID19 mRNA N=64385	01/01/2009-03/18/2022 NON-COVID19 N=15797	12/14-03/18 Chi-Square	12/14-03/18 PRR	12/14-03/18 LCL	12/14-03/18 UCL
COVID-19	16654	40	5046.30	102.15	74.94	139.25
COVID-19 PNEUMONIA	3901	7	988.42	136.73	65.15	286.94
LUNG OPACITY	1535	7	366.94	53.80	25.61	113.02
PULMONARY THROMBOSIS	524	3	121.53	42.85	13.78	133.29
POSITIVE AIRWAY PRESSURE THERAPY	648	6	145.87	26.50	11.86	59.19
ANTICOAGULANT THERAPY	3043	57	649.22	13.10	10.08	17.01
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	878	20	174.18	10.77	6.92	16.77
THROMBECTOMY	312	5	64.94	15.31	6.33	37.03
ILLNESS	459	10	90.94	11.26	6.02	21.07
APPENDICITIS	519	16	94.01	7.96	4.84	13.08
PULMONARY EMBOLISM	2578	116	416.66	5.45	4.53	6.56
THROMBOSIS	1305	60	204.65	5.34	4.12	6.91
EPINEPHRINE	285	9	50.60	7.77	4.00	15.08
UNEVALUABLE EVENT	2049	106	304.94	4.74	3.90	5.76
LEFT VENTRICULAR FAILURE	193	6	34.06	7.89	3.50	17.78
BELL'S PALSY	441	21	66.51	5.15	3.33	7.98
ANOSMIA	355	16	54.82	5.44	3.30	8.98
DEATH	8428	608	1082.41	3.40	3.14	3.69
STENT PLACEMENT	245	11	37.55	5.46	2.99	10.00
RESPIRATORY RATE INCREASED	1010	65	127.55	3.81	2.97	4.90
HYPERVOLAEMIA	177	7	28.46	6.20	2.92	13.20
PULMONARY INFARCTION	111	3	19.96	9.08	2.88	28.57
CARDIAC FAILURE ACUTE	260	13	37.70	4.91	2.81	8.56
GENERAL PHYSICAL CONDITION ABNORMAL	229	11	33.83	5.11	2.79	9.35
APPENDICECTOMY	405	24	53.36	4.14	2.74	6.25
BLOOD LOSS ANAEMIA	134	5	21.82	6.58	2.69	16.05
BLOOD PRESSURE SYSTOLIC INCREASED	393	24	50.65	4.02	2.66	6.06
RESPIRATORY RATE DECREASED	217	11	31.05	4.84	2.64	8.87
END STAGE RENAL DISEASE	143	6	22.20	5.85	2.58	13.23
ISCHAEMIC STROKE	438	30	51.72	3.58	2.48	5.18
IMMUNE THROMBOCYTOPENIA	268	16	34.77	4.11	2.48	6.80
ACUTE RESPIRATORY FAILURE	3159	286	294.93	2.71	2.40	3.05
HEART RATE DECREASED	619	48	65.69	3.16	2.36	4.24
ACUTE LEFT VENTRICULAR FAILURE	117	5	17.83	5.74	2.35	14.05
OXYGEN SATURATION DECREASED	2123	193	194.08	2.70	2.33	3.12
ACUTE MYOCARDIAL INFARCTION	1254	110	118.03	2.80	2.30	3.40
TROPONIN INCREASED	334	24	37.58	3.41	2.26	5.16
CORONARY ARTERIAL STENT INSERTION	233	15	28.45	3.81	2.26	6.42
IMMUNISATION	138	7	19.38	4.84	2.26	10.33
DEEP VEIN THROMBOSIS	1315	119	119.28	2.71	2.25	3.27
CEREBROVASCULAR ACCIDENT	2494	242	210.33	2.53	2.22	2.88
HOSPICE CARE	214	14	25.73	3.75	2.18	6.44
GENERAL PHYSICAL HEALTH DETERIORATION	807	73	72.44	2.71	2.14	3.44
CHRONIC KIDNEY DISEASE	496	42	47.69	2.90	2.12	3.97
SUPERINFECTION	82	3	13.06	6.71	2.12	21.22
DRUG INEFFECTIVE	129	7	17.33	4.52	2.11	9.67
GENERAL SYMPTOM	105	5	15.05	5.15	2.10	12.63
VENTRICULAR HYPOKINESIA	137	8	17.59	4.20	2.06	8.57
CARDIAC FAILURE	535	48	48.09	2.73	2.04	3.67
CORONARY ARTERY OCCLUSION	176	12	20.29	3.60	2.01	6.46
HYPOXIA	3280	361	230.27	2.23	2.00	2.48
CHRONIC LEFT VENTRICULAR FAILURE	122	7	15.75	4.28	2.00	9.16
LUNG INFILTRATION	968	99	73.60	2.40	1.95	2.95
PHARYNGEAL SWELLING	392	35	35.19	2.75	1.95	3.88
CEREBRAL INFARCTION	381	34	34.20	2.75	1.94	3.90
DEMENTIA	341	30	31.05	2.79	1.92	4.05
LUNG CONSOLIDATION	292	25	27.34	2.87	1.91	4.31
INFUSION	106	6	13.69	4.33	1.90	9.86
AUTOPSY	317	28	28.67	2.78	1.89	4.09
MULTIPLE ORGAN DYSFUNCTION SYNDROME	241	20	23.23	2.96	1.87	4.66
MYOCARDIAL INFARCTION	1227	136	82.24	2.21	1.86	2.64
PNEUMONIA BACTERIAL	283	25	25.50	2.78	1.85	4.18
AGEUSIA	461	46	35.76	2.46	1.82	3.33
HOSPITALISATION	111	7	13.30	3.89	1.81	8.35
PULSELESS ELECTRICAL ACTIVITY	293	27	25.06	2.66	1.80	3.95
CARDIAC ARREST	1432	170	84.79	2.07	1.76	2.42
CARDIO-RESPIRATORY ARREST	574	63	38.45	2.24	1.72	2.90
EMBOLIC STROKE	86	5	10.74	4.22	1.71	10.39
PULSE ABSENT	574	64	37.40	2.20	1.70	2.85
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	211	19	18.37	2.72	1.70	4.36
ELECTRIC SHOCK SENSATION	113	8	12.31	3.47	1.69	7.10
APPENDICITIS PERFORATED	103	7	11.56	3.61	1.68	7.76
PNEUMONIA VIRAL	138	11	13.55	3.08	1.67	5.69
CEREBRAL HAEMORRHAGE	370	40	25.14	2.27	1.64	3.14
HYPERTENSIVE EMERGENCY	73	4	9.36	4.48	1.64	12.25
ATYPICAL PNEUMONIA	90	6	10.16	3.68	1.61	8.41
CARDIOGENIC SHOCK	228	23	17.01	2.43	1.58	3.73
RETINAL ARTERY OCCLUSION	79	5	9.20	3.88	1.57	9.57
BLOOD PRESSURE DIASTOLIC DECREASED	96	7	10.06	3.36	1.56	7.25
EXTRA DOSE ADMINISTERED	177	17	14.02	2.55	1.55	4.20
BLOOD PRESSURE SYSTOLIC DECREASED	68	4	8.24	4.17	1.52	11.43
TASTE DISORDER	163	16	12.46	2.50	1.50	4.18
RESPIRATORY SYMPTOM	185	19	13.30	2.39	1.49	3.83
DRAINAGE	58	3	7.52	4.74	1.49	15.14
DEMENTIA ALZHEIMER'S TYPE	105	9	9.33	2.86	1.45	5.65
EJECTION FRACTION DECREASED	179	19	12.18	2.31	1.44	3.71
CORONARY ARTERY THROMBOSIS	56	3	7.08	4.58	1.43	14.63
OROPHARYNGEAL DISCOMFORT	109	10	8.91	2.67	1.40	5.11
ATRIOVENTRICULAR BLOCK COMPLETE	77	6	7.40	3.15	1.37	7.22
CARDIAC FLUTTER	135	14	9.38	2.37	1.36	4.10
SUDDEN DEATH	158	18	9.42	2.15	1.32	3.51
HEPATIC CIRRHOSIS	122	13	8.05	2.30	1.30	4.08
GASTROINTESTINAL WALL THICKENING	51	3	5.97	4.17	1.30	13.36
PALLIATIVE CARE	79	7	6.56	2.77	1.28	6.00
ANGINA UNSTABLE	50	3	5.75	4.09	1.28	13.11
THALAMIC INFARCTION	57	4	5.86	3.50	1.27	9.63
AORTIC ANEURYSM	90	9	6.40	2.45	1.24	4.87
IMPAIRED SELF-CARE	70	6	5.98	2.86	1.24	6.59
HAEMORRHAGIC STROKE	109	12	6.73	2.23	1.23	4.04
PULSE ABNORMAL	108	12	6.55	2.21	1.22	4.01
THROMBOLYSIS	55	4	5.44	3.37	1.22	9.31
LYMPHADENOPATHY MEDIASTINAL	94	10	6.07	2.31	1.20	4.43
PERICARDIAL DRAINAGE	86	9	5.66	2.34	1.18	4.66
JUGULAR VEIN DISTENSION	53	4	5.03	3.25	1.18	8.98
CARDIAC ABLATION	104	12	5.85	2.13	1.17	3.86
CHOLECYSTITIS ACUTE	46	3	4.89	3.76	1.17	12.09
HILAR LYMPHADENOPATHY	52	4	4.82	3.19	1.15	8.82
IMPLANTABLE DEFIBRILLATOR INSERTION	76	8	4.88	2.33	1.13	4.83
ACUTE CORONARY SYNDROME	70	7	4.83	2.45	1.13	5.33
ACQUIRED DIAPHRAGMATIC EVENTRATION	44	3	4.46	3.60	1.12	11.59
RETINAL VEIN OCCLUSION	44	3	4.46	3.60	1.12	11.59
SUDDEN CARDIAC DEATH	61	6	4.24	2.49	1.08	5.77
HEPATIC LESION	49	4	4.21	3.01	1.08	8.33
PERIPHERAL ISCHAEMIA	49	4	4.21	3.01	1.08	8.33
SYSTOLIC DYSFUNCTION	49	4	4.21	3.01	1.08	8.33
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	42	3	4.05	3.43	1.06	11.08
ARTERIAL OCCLUSIVE DISEASE	61	6	4.24	2.49	1.08	5.77
VACCINE BREAKTHROUGH INFECTION	2580	2	648.16	316.50	79.12	1266.06
EXPOSURE TO SARS-COV-2	662	1	160.28	162.42	22.85	1154.67
ASYMPTOMATIC COVID-19	492	2	115.77	60.36	15.05	241.99
BLOOD PRESSURE DIASTOLIC INCREASED	173	2	37.02	21.22	5.27	85.53
CEREBRAL VENOUS SINUS THROMBOSIS	143	1	31.75	35.09	4.91	250.76
SUSPECTED COVID-19	130	1	28.56	31.90	4.46	228.12
OFF LABEL USE	95	1	19.99	23.31	3.25	167.17
RIGHT VENTRICULAR DYSFUNCTION	83	1	17.06	20.36	2.84	146.27
CEREBRAL ARTERY OCCLUSION	92	2	17.28	11.29	2.78	45.80
INTRACARDIAC THROMBUS	88	2	16.31	10.80	2.66	43.84
CEREBELLAR STROKE	74	1	14.87	18.16	2.52	130.59
LYMPHOPENIA	73	1	14.63	17.91	2.49	128.85
CEREBRAL MASS EFFECT	70	1	13.90	17.17	2.39	123.63
RIGHT VENTRICULAR DILATATION	67	1	13.17	16.44	2.28	118.40
CARDIAC ASSISTANCE DEVICE USER	72	2	12.47	8.83	2.17	35.99
DYSPNOEA AT REST	70	2	12.00	8.59	2.11	35.01
PERCUTANEOUS CORONARY INTERVENTION	70	2	12.00	8.59	2.11	35.01
PERIPHERAL ARTERY THROMBOSIS	68	2	11.52	8.34	2.04	34.03
MYOCARDIAL STRAIN	59	1	11.23	14.48	2.01	104.47
PORTAL VEIN THROMBOSIS	66	2	11.05	8.10	1.98	33.05
PULMONARY PAIN	62	2	10.10	7.61	1.86	31.09
HAEMOFILTRATION	52	1	9.54	12.76	1.76	92.28
IMPLANTABLE CARDIAC MONITOR INSERTION	52	1	9.54	12.76	1.76	92.28
CRITICAL ILLNESS	57	2	8.93	6.99	1.71	28.64
MESENTERIC VEIN THROMBOSIS	49	1	8.82	12.02	1.66	87.06
NIH STROKE SCALE	47	1	8.34	11.53	1.59	83.57
NEUROLOGIC NEGLECT SYNDROME	46	1	8.10	11.29	1.56	81.83
NIH STROKE SCALE ABNORMAL	45	1	7.86	11.04	1.52	80.09
THROMBOEMBOLECTOMY	45	1	7.86	11.04	1.52	80.09
CORONARY ARTERY DISSECTION	44	1	7.63	10.80	1.49	78.35
JUGULAR VEIN THROMBOSIS	44	1	7.63	10.80	1.49	78.35
INTERNAL HAEMORRHAGE	48	2	6.84	5.89	1.43	24.22
COR PULMONALE ACUTE	42	1	7.15	10.30	1.42	74.87
LEFT VENTRICULAR DILATATION	40	1	6.67	9.81	1.35	71.38
NIH STROKE SCALE SCORE INCREASED	40	1	6.67	9.81	1.35	71.38
AORTIC DISSECTION	43	2	5.70	5.28	1.28	21.77
LUNG ASSIST DEVICE THERAPY	42	2	5.47	5.15	1.25	21.28
MYOCARDIAL FIBROSIS	42	2	5.47	5.15	1.25	21.28
CORONARY ANGIOPLASTY	37	1	5.96	9.08	1.25	66.16
CARDIAC FAILURE CHRONIC	40	2	5.02	4.91	1.19	20.30
PERIPHERAL ARTERY OCCLUSION	35	1	5.49	8.59	1.18	62.68
ARTERIAL CATHETERISATION	38	2	4.58	4.66	1.12	19.32
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	33	1	5.03	8.10	1.11	59.19
HEPATIC MASS	33	1	5.03	8.10	1.11	59.19
BREATH SOUNDS ABSENT	37	2	4.36	4.54	1.09	18.83
SUBDURAL HAEMORRHAGE	37	2	4.36	4.54	1.09	18.83
ACUTE CARDIAC EVENT	32	1	4.79	7.85	1.07	57.45
MITRAL VALVE CALCIFICATION	29	1	4.10	7.12	0.97	52.23
IMPAIRED QUALITY OF LIFE	43	4	3.05	2.64	0.95	7.35
PAIN ASSESSMENT	9	1	0.14	2.21	0.28	17.43